

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
  - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
  - FADED TEXT
  - ILLEGIBLE TEXT
  - SKEWED/SLANTED IMAGES
  - COLORED PHOTOS
  - BLACK OR VERY BLACK AND WHITE DARK PHOTOS
  - GRAY SCALE DOCUMENTS
- 

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

**THIS PAGE BLANK (USPTO)**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>C12N 15/64, 15/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/06204</b>  <b>(43) International Publication Date:</b> 16 April 1992 (16.04.92)
<b>(21) International Application Number:</b> PCT/US91/07149 <b>(22) International Filing Date:</b> 27 September 1991 (27.09.91)  <b>(30) Priority data:</b> 590,219 28 September 1990 (28.09.90) US  <b>(71) Applicant:</b> IXSYS, INC. [US/US]; 3550 General Atomics Court, Suite L103, San Diego, CA 92121 (US).  <b>(72) Inventor:</b> HUSE, William, D. ; 471 Avenida Primavera, Del Mar, CA 92014 (US).  <b>(74) Agents:</b> CAMPBELL, Cathryn et al.; Pretty, Schroeder, Brueggemann & Clark, 444 South Flower Street, Suite 2000, Los Angeles, CA 90071 (US).		<b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU*, TD (OAPI patent), TG (OAPI patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS  <b>(57) Abstract</b>  A composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.		

**+ DESIGNATIONS OF "SU"**

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				



SURFACE EXPRESSION LIBRARIES  
OF HETEROMERIC RECEPTORS

BACKGROUND OF THE INVENTION

This invention relates generally to recombinant  
5 expression of heteromeric receptors and, more particularly,  
to expression of such receptors on the surface of  
filamentous bacteriophage.

Antibodies are heteromeric receptors generated by a  
vertebrates organism's immune system which bind to an  
10 antigen. The molecules are composed of two heavy and two  
light chains disulfide bonded together. Antibodies have  
the appearance of a "Y" - shaped structure and the antigen  
binding portion being located at the end of both short arms  
of the Y. The region on the heavy and light chain  
15 polypeptides which corresponds to the antigen binding  
portion is known as variable region. The differences  
between antibodies within this region are primarily  
responsible for the variation in binding specificities  
between antibody molecules. The binding specificities are  
20 a composite of the antigen interactions with both heavy and  
light chain polypeptides.

The immune system has the capability of generating an  
almost infinite number of different antibodies. Such a  
large diversity is generated primarily through  
25 recombination to form the variable regions of each chain  
and through differential pairing of heavy and light chains.  
The ability to mimic the natural immune system and generate  
antibodies that bind to any desired molecule is valuable  
because such antibodies can be used for diagnostic and  
30 therapeutic purposes.

Until recently, generation of antibodies against a

desired molecule was accomplished only through manipulation of natural immune responses. Methods included classical immunization techniques of laboratory animals and monoclonal antibody production. Generation of monoclonal antibodies is laborious and time consuming. It involves a series of different techniques and is only performed on animal cells. Animal cells have relatively long generation times and require extra precautions to be taken compared to procaryotic cells to ensure viability of the cultures. ,

10       A method for the generation of a large repertoire of diverse antibody molecules in bacteria has been described, Huse et al., Science, 246, 1275-1281 (1989), which is herein incorporated by reference. The method uses the bacteriophage lambda as the vector. The lambda vector is  
15 a long, linear double-stranded DNA molecule. Production of antibodies using this vector involves the cloning of heavy and light chain populations of DNA sequences into separate vectors. The vectors are subsequently combined randomly to form a single vector which directs the coexpression of  
20 heavy and light chains to form antibody fragments. A disadvantage to this method is that undesired combinations of vector portions are brought together when generating the coexpression vector. Although these undesired combinations do not produce viable phage, they do however, result in a  
25 significant loss of sequences from the population and, therefore, a loss in diversity of the number of different combinations which can be obtained between heavy and light chains. Additionally, the size of the lambda phage gene is large compared to the genes that encode the antibody  
30 segments. This makes the lambda system inherently more difficult to manipulate as compared to other available vector systems.

There thus exists a need for a method to generate diverse populations of heteromeric receptors which mimics  
35 the natural immune system, which is fast and efficient and

results in only desired combinations without loss of diversity. The present invention satisfies these needs and provides related advantages as well.

#### SUMMARY OF THE INVENTION

5       The invention relates to a plurality of cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor, said heteromeric receptors being expressed on the surface of a cell, preferably one which  
10 produces filamentous bacteriophage, such as M13. Vectors, cloning systems and methods of making and screening the heteromeric receptors are also provided.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of the two vectors  
15 used for surface expression library construction from heavy and light chain libraries. M13IX30 (Figure 1A) is the vector used to clone the heavy chain sequences (open box). The single-headed arrow represents the Lac p/o expression sequences and the double-headed arrow represents the  
20 portion of M13IX30 which is to be combined with M13IX11. The amber stop codon and relevant restriction sites are also shown. M13IX11 (Figure 1B) is the vector used to clone the light chain sequences (hatched box). Thick lines represent the pseudo-wild type (gVIII) and wild type  
25 (gVIII) gene VIII sequences. The double-headed arrow represents the portion of M13IX11 which is to be combined with M13IX30. Relevant restriction sites are also shown. Figure 1C shows the joining of vector population from heavy and light chain libraries to form the functional surface  
30 expression vector M13IXHL. Figure 1D shows the generation of a surface expression library in a non-suppressor strain and the production of phage. The phage are used to infect a suppressor strain (Figure 1E) for surface expression and

screening of the library.

Figure 2 is the nucleotide sequence of M13IX30 (SEQ ID NO: 1).

Figure 3 is the nucleotide sequence of M13IX11 (SEQ ID NO:2).

Figure 4 is the nucleotide sequence of M13IX34 (SEQ ID NO: 3) .

Figure 5 is the nucleotide sequence of M13IX13 (SEQ ID NO: 4).

Figure 6 is the nucleotide sequence of M13IX60 (SEQ ID NO: 5).

#### DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to simple and efficient methods to generate a large repertoire of diverse combinations of heteromeric receptors. The method is advantageous in that only proper combinations of vector portions are randomly brought together for the coexpression of different DNA sequences without loss of population size or diversity. The receptors can be expressed on the surface of cells, such as those producing filamentous bacteriophage, which can be screened in large numbers. The nucleic acid sequences encoding the receptors be readily characterized because the filamentous bacteriophage produce single strand DNA for efficient sequencing and mutagenesis methods. The heteromeric receptors so produced are useful in an unlimited number of diagnostic and therapeutic procedures.

In one embodiment, two populations of diverse heavy (Hc) and light (Lc) chain sequences are synthesized by

polymerase chain reaction (PCR). These populations are cloned into separate M13-based vector containing elements necessary for expression. The heavy chain vector contains a gene VIII (gVIII) coat protein sequence so that translation of the Hc sequences produces gVIII-Hc fusion proteins. The populations of two vectors are randomly combined such that only the vector portions containing the Hc and Lc sequences are joined into a single circular vector. The combined vector directs the coexpression of both Hc and Lc sequences for assembly of the two polypeptides and surface expression on M13. A mechanism also exists to control the expression of gVIII-Hc fusion proteins during library construction and screening.

As used herein, the term "heteromeric receptors" refers to proteins composed of two or more subunits which together exhibit binding activity toward particular molecule. It is understood that the term includes the subunit fragments so long as assembly of the polypeptides and function of the assembled complex is retained. Heteromeric subunits include, for example, antibodies and fragments thereof such as Fab and (Fab)<sub>2</sub> portions, T cell receptors, integrins, hormone receptors and transmitter receptors.

As used herein, the term "preselected molecule" refers to a molecule which is chosen from a number of choices. The molecule can be, for example, a protein or peptide, or an organic molecule such as a drug. Benzodiazepam is a specific example of a preselected molecule.

As used herein, the term "coexpression" refers to the expression of two or more nucleic acid sequences usually expressed as separate polypeptides. For heteromeric receptors, the coexpressed polypeptides assemble to form the heteromer. Therefore, "expression elements" as used herein, refers to sequences necessary for the

transcription, translation, regulation and sorting of the expressed polypeptides which make up the heteromeric receptors. The term also includes the expression of two subunit polypeptides which are linked but are able to  
5 assemble into a heteromeric receptor. A specific example of coexpression of linked polypeptides is where Hc and Lc polypeptides are expressed with a flexible peptide or polypeptide linker joining the two subunits into a single chain. The linker is flexible enough to allow association  
10 of Hc and Lc portions into a functional Fab fragment.

The invention provides for a composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a  
15 heteromeric receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.

DNA sequences encoding the polypeptides of heteromeric receptors are obtained by methods known to one  
20 skilled in the art. Such methods include, for example, cDNA synthesis and polymerase chain reaction (PCR). The need will determine which method or combinations of methods is to be used to obtain the desired populations of sequences. Expression can be performed in any compatible  
25 vector/host system. Such systems include, for example, plasmids or phagemids in procaryotes such as E. coli, yeast systems and other eucaryotic systems such as mammalian cells, but will be described herein in context with its presently preferred embodiment, i.e. expression on the  
30 surface of filamentous bacteriophage. Filamentous bacteriophage include, for example, M13, fl and fd. Additionally, the heteromeric receptors can also be expressed in soluble or secreted form depending on the need and the vector/host system employed.

Expression of heteromeric receptors such as antibodies or functional fragments thereof on the surface of M13 can be accomplished, for example, using the vector system shown in Figure 1. Construction of the vectors enabling one of ordinary skill to make them are explicitly set out in Example I. The complete nucleotide sequences are given in Figures 2 and 3 (SEQ ID NOS: 1 and 2). This system produces randomly combined populations of heavy (Hc) and light (Lc) chain antibody fragments functionally linked to expression elements. The Hc polypeptide is produced as a fusion protein with the M13 coat protein encoded by gene VIII. The gVIII-Hc fusion protein therefore anchors the assembled Hc and Lc polypeptides on the surface of M13. The diversity of Hc and Lc combinations obtained by this system can be  $5 \times 10^7$  or greater. Diversity of less than  $5 \times 10^7$  can also be obtained and will be determined by the need and type of heteromeric receptor to be expressed.

Populations of Hc and Lc encoding sequences to be combined into a vector for coexpression are each cloned into separate vectors. For the vectors shown in Figure 1, diverse populations of sequences encoding Hc polypeptides are cloned into M13IX30 (SEQ ID NO: 1). Sequences encoding Lc polypeptides are cloned into M13IX11 (SEQ ID NO: 2). The populations are inserted between the Xho I-Spe I or Stu I restriction enzyme sites in M13IX30 and between the Sac I-Xba I or Eco RV sites in M13IX11 (Figures 1A and B, respectively).

The populations of Hc and Lc sequences inserted into the vectors can be synthesized with appropriate restriction recognition sequences flanking opposite ends of the encoding sequences but this is not necessary. The sites allow annealing and ligation in-frame with expression elements of these sequences into a double-stranded vector restricted with the appropriate restriction nzyme. Alternatively, and a preferred embodiment, the Hc and Lc

sequences can be inserted into the vector without restriction of the DNA. This method of cloning is beneficial because naturally encoded restriction enzyme sites may be present within the sequences, thus, causing  
5 destruction of the sequence when treated with a restriction enzyme. For cloning without restriction, the sequences are treated briefly with a 3' to 5' exonuclease such as T4 DNA polymerase or exonuclease III. A 5' to 3' exonuclease will also accomplish the same function. The protruding 5'  
10 termini which remains should be complementary to single-stranded overhangs within the vector which remain after restriction at the cloning site and treatment with exonuclease. The exonuclease treated inserts are annealed with the restricted vector by methods known to one skilled  
15 in the art. The exonuclease method decreases background and is easier to perform.

The vector used for Hc populations, M13IX30 (Figure 1A; SEQ ID NO: 1) contains, in addition to expression elements, a sequence encoding the pseudo-wild type gVIII  
20 product downstream and in frame with the cloning sites. This gene encodes the wild type M13 gVIII amino acid sequence but has been changed at the nucleotide level to reduce homologous recombination with the wild type gVIII contained on the same vector. The wild type gVIII is  
25 present to ensure that at least some functional, non-fusion coat protein will be produced. The inclusion of a wild type gVIII therefore reduces the possibility of non-viable phage production and biological selection against certain peptide fusion proteins. Differential regulation of the  
30 two genes can also be used to control the relative ratio of the pseudo and wild type proteins.

Also contained downstream and in frame with the cloning sites is an amber stop codon. The stop codon is located between the inserted Hc sequences and the gVIII  
35 sequenc and is in frame. As was the function of the wild



type gVIII, the amber stop codon also reduces biological selection when combining vector portions to produce functional surface expression vectors. This is accomplished by using a non-suppressor (sup 0) host strain because the non-suppressor strains will terminate expression after the Hc sequences but before the pseudo gVIII sequences. Therefore, the pseudo gVIII will essentially never be expressed on the phage surface under these circumstances. Instead, only soluble Hc polypeptides will be produced. Expression in a non-suppressor host strain can be advantageously utilized when one wishes to produce large populations of antibody fragments. Stop codons other than amber, such as opal and ochre, or molecular switches, such as inducible repressor elements, can also be used to unlink peptide expression from surface expression.

The vector used for Lc populations, M13IX11 (SEQ ID NO: 2), contains necessary expression elements and cloning sites for the Lc sequences, Figure 1B. As with M13IX30, upstream and in frame with the cloning sites is a leader sequence for sorting to the phage surface. Additionally, a ribosome binding site and Lac Z promoter/operator elements are also present for transcription and translation of the DNA sequences.

Both vectors contain two pairs of Mlu I-Hind III restriction enzyme sites (Figures 1A and B) for joining together the Hc and Lc encoding sequences and their associated vector sequences. Mlu I and Hind III are non-compatible restriction sites. The two pairs are symmetrically orientated about the cloning site so that only the vector portions containing the sequences to be expressed are exactly combined into a single vector. The two pairs of sites are oriented identically with respect to one another on both vectors and the DNA between the two sites must be homologous enough between both vectors to

allow annealing. This orientation allows cleavage of each circular vector into two portions and combination of essential components within each vector into a single circular vector where the encoded polypeptides can be coexpressed (Figure 1C).

Any two pairs of restriction enzyme sites can be used so long as they are symmetrically orientated about the cloning site and identically orientated on both vectors. The sites within each pair, however, should be non-identical or able to be made differentially recognized as a cleavage substrate. For example, the two pairs of restriction sites contained within the vectors shown in Figure 1 are Mlu I and Hind III. The sites are differentially cleavable by Mlu I and Hind III respectively. One skilled in the art knows how to substitute alternative pairs of restriction enzyme sites for the Mlu I-Hind III pairs described above. Also, instead of two Hind III and two Mlu I sites, a Hind III and Not I site can be paired with a Mlu I and a Sal I site, for example.

The combining step randomly brings together different Hc and Lc encoding sequences within the two diverse populations into a single vector (Figure 1C; M13IXHL). The vector sequences donated from each independent vector, M13IX30 and M13IX11, are necessary for production of viable phage. Also, since the pseudo gVIII sequences are contained in M13IX30, coexpression of functional antibody fragments as Lc associated gVIII-Hc fusion proteins cannot be accomplished on the phage surface until the vector sequences are linked as shown in M13IXHL.

The combining step is performed by restricting each population of Hc and Lc containing vectors with Mlu I and Hind III, respectively. The 3' termini of each restricted vector population is digested with a 3' to 5' exonuclease

as described above for inserting sequences into the cloning sites. The vector populations are mixed, allowed to anneal and introduced into an appropriate host. A non-suppressor host (Figure 1D) is preferably used during initial construction of the library to ensure that sequences are not selected against due to expression as fusion proteins. Phage isolated from the library constructed in a non-suppressor strain can be used to infect a suppressor strain for surface expression of antibody fragments.

10       A method for selecting a heteromeric receptor exhibiting binding activity toward a preselected molecule from a population of diverse heteromeric receptors, comprising: (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a  
15       diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site; (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second  
20       polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector; (c) combining the vector products of step (a) and (b) under conditions which allow only the operational  
25       combination of vector sequences containing said first and second DNA sequences; (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences; and (e) determining the heteromeric  
30       receptors which bind to said preselected molecule. The invention also provides for determining the nucleic acid sequences encoding such polypeptides as well.

Surface expression of the antibody library is performed in an amber suppressor strain. As described  
35       above, the amber stop codon between the Hc sequence and the

gVIII sequence unlinks the two components in a non-suppressor strain. Isolating the phage produced from the non-suppressor strain and infecting a suppressor strain will link the Hc sequences to the gVIII sequence during  
5 expression (Figure 1E). Culturing the suppressor strain after infection allows the coexpression on the surface of M13 of all antibody species within the library as gVIII fusion proteins (gVIII-Fab fusion proteins). Alternatively, the DNA can be isolated from the non-  
10 suppressor strain and then introduced into a suppressor strain to accomplish the same effect.

The level of expression of gVIII-Fab fusion proteins can additionally be controlled at the transcriptional level. Both polypeptides of the gVIII-Fab fusion proteins  
15 are under the inducible control of the Lac Z promoter/operator system. Other inducible promoters can work as well and are known by one skilled in the art. For high levels of surface expression, the suppressor library is cultured in an inducer of the Lac Z promoter such as  
20 isopropylthio- $\beta$ -galactoside (IPTG). Inducible control is beneficial because biological selection against non-functional gVIII-Fab fusion proteins can be minimized by culturing the library under non-expressing conditions. Expression can then be induced only at the time of  
25 screening to ensure that the entire population of antibodies within the library are accurately represented on the phage surface. Also, this can be used to control the valency of the antibody on the phage surface.

The surface expression library is screened for  
30 specific Fab fragments which bind preselected molecules by standard affinity isolation procedures. Such methods include, for example, panning, affinity chromatography and solid phase blotting procedures. Panning as described by Parmley and Smith. Gene 73:305-318 (1988), which is  
35 incorporated herein by reference, is preferred because high

titers of phage can be screened easily, quickly and in small volumes. Furthermore, this procedure can select minor Fab fragments species within the population, which otherwise would have been undetectable, and amplified to substantially homogenous populations. The selected Fab fragments can be characterized by sequencing the nucleic acids encoding the polypeptides after amplification of the phage population.

The following examples are intended to illustrate but not limit the invention.

#### EXAMPLE I

##### Construction, Expression and Screening of Antibody Fragments on the Surface of M13

This example shows the synthesis of a diverse population of heavy (Hc) and light (Lc) chain antibody fragments and their expression on the surface of M13 as gene VIII-Fab fusion proteins. The expressed antibodies derive from the random mixing and coexpression of a Hc and Lc pair. Also demonstrated is the isolation and characterization of the expressed Fab fragments which bind benzodiazepam (BDP) and their corresponding nucleotide sequence.

##### Isolation of mRNA and PCR Amplification of Antibody Fragments

The surface expression library is constructed from mRNA isolated from a mouse that had been immunized with KLH-coupled benzodiazepam (BDP). BDP was coupled to keyhole limpet hemocyanin (KLH) using the techniques described in Antibodies: A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor, New York (1988), which is incorporated herein by reference. Briefly, 10.0 milligrams (mg) of keyhole limpet hemocyanin and 0.5 mg of BDP with a

glutaryl spacer arm N-hydroxysuccinimide linker appendages. Coupling was performed as in Jonda et al., Science, 241:1188 (1988), which is incorporated herein by reference. The KLH-BDP conjugate was removed by gel filtration  
5 chromatography through Sephadex G-25.

The KLH-BDP conjugate was prepared for injection into mice by adding 100  $\mu$ g of the conjugate to 250  $\mu$ l of phosphate buffered saline (PBS). An equal volume of complete Freund's adjuvant was added and emulsified the  
10 entire solution for 5 minutes. Mice were injected with 300  $\mu$ l of the emulsion. Injections were given subcutaneously at several sites using a 21 gauge needle. A second immunization with BDP was given two weeks later. This injection was prepared as follows: 50  $\mu$ g of BDP was  
15 diluted in 250  $\mu$ l of PBS and an equal volume of alum was mixed with the solution. The mice were injected intraperitoneally with 500  $\mu$ l of the solution using a 23 gauge needle. One month later the mice were given a final injection of 50  $\mu$ g of the conjugate diluted to 200  $\mu$ l in  
20 PBS. This injection was given intravenously in the lateral tail vein using a 30 gauge needle. Five days after this final injection the mice were sacrificed and total cellular RNA was isolated from their spleens.

Total RNA was isolated from the spleen of a single  
25 mouse immunized as described above by the method of Chomczynski and Sacchi, Anal. Biochem., 162:156-159 (1987), which is incorporated herein by reference. Briefly, immediately after removing the spleen from the immunized mouse, the tissue was homogenized in 10 ml of a denaturing  
30 solution containing 4.0 M guanine isothiocyanate, 0.25 M sodium citrate at pH 7.0, and 0.1 M 2-mercaptoethanol using a glass homogenizer. One ml of sodium acetate at a concentration of 2 M at pH 4.0 was mixed with the homogenized spleen. One ml of saturated phenol was also  
35 mixed with the denaturing solution containing the

homogenized spleen. Two ml of a chloroform:isoamyl alcohol (24:1 v/v) mixture was added to this homogenate. The homogenate was mixed vigorously for ten seconds and maintained on ice for 15 minutes. The homogenate was then transferred to a thick-walled 50 ml polypropylene centrifuge tube (Fisher Scientific Company, Pittsburgh, PA). The solution was centrifuged at 10,000 x g for 20 minutes at 4°C. The upper RNA-containing aqueous layer was transferred to a fresh 50 ml polypropylene centrifuge tube and mixed with an equal volume of isopropyl alcohol. This solution was maintained at -20°C for at least one hour to precipitate the RNA. The solution containing the precipitated RNA was centrifuged at 10,000 x g for twenty minutes at 4°C. The pelleted total cellular RNA was collected and dissolved in 3 ml of the denaturing solution described above. Three mls of isopropyl alcohol was added to the resuspended total cellular RNA and vigorously mixed. This solution was maintained at -20°C for at least 1 hour to precipitate the RNA. The solution containing the precipitated RNA was centrifuged at 10,000 x g for ten minutes at 4°C. The pelleted RNA was washed once with a solution containing 75% ethanol. The pelleted RNA was dried under vacuum for 15 minutes and then resuspended in dimethyl pyrocarbonate (DEPC) treated (DEPC-H<sub>2</sub>O) H<sub>2</sub>O.

Poly A<sup>+</sup> RNA for use in first strand cDNA synthesis was prepared from the above isolated total RNA using a spin-column kit (Pharmacia, Piscataway, NJ) as recommended by the manufacturer. The basic methodology has been described by Aviv and Leder, Proc. Natl. Acad. Sci., USA, 69:1408-1412 (1972), which is incorporated herein by reference. Briefly, one half of the total RNA isolated from a single immunized mouse spleen prepared as described above was resuspended in one ml of DEPC-treated dH<sub>2</sub>O and maintained at 65°C for five minutes. One ml of 2x high salt loading buffer (100 mM Tris-HCL at pH 7.5, 1 M sodium chloride, 2.0 mM disodium ethylene diamine tetraacetic acid (EDTA) at pH

8.0, and 0.2% sodium dodecyl sulfate (SDS)) was added to the resuspended RNA and the mixture was allowed to cool to room temperature. The mixture was then applied to an oligo-dT (Collaborative Research Type 2-or-Type-3 Bedford, MA) column that was previously prepared by washing the oligo-dT with a solution containing 0.1 M sodium hydroxide and 5 mM EDTA and then equilibrating the column with DEPC-treated dH<sub>2</sub>O. The eluate was collected in a sterile polypropylene tube and reapplied to the same column after heating the eluate for 5 minutes at 65°C. The oligo dT column was then washed with 2 ml of high salt loading buffer consisting of 50 mM Tris-HCL at pH 7.5, 500 mM sodium chloride, 1 mM EDTA at pH 8.0 and 0.1% SDS. The oligo dT column was then washed with 2 ml of 1 X medium salt buffer (50 mM Tris-HCL at pH 7.5, 100 mM sodium chloride, 1 mM EDTA at pH 8.0 and 0.1% SDS). The mRNA was eluted with 1 ml of buffer consisting of 10 mM Tris-HCL at pH 7.5, 1 mM EDTA at pH 8.0 and 0.05% SDS. The messenger RNA was purified by extracting this solution with phenol/chloroform followed by a single extraction with 100% chloroform, ethanol precipitated and resuspended in DEPC treated dH<sub>2</sub>O.

In preparation for PCR amplification, mRNA was used as a template for cDNA synthesis. In a typical 250 µl reverse transcription reaction mixture, 5-10 µg of spleen mRNA in water was first annealed with 500 ng (0.5 pmol) of either the 3' V<sub>H</sub> primer (primer 12, Table I) or the 3' V<sub>L</sub> primer (primer 9, Table II) at 65°C for 5 minutes. Subsequently, the mixture was adjusted to contain 0.8 mM dATP, 0.8 mM dCTP, 0.8 mM dGTP, 0.8 mM dTTP, 100 mM Tris-HCL (pH 8.6), 10 mM MgCl<sub>2</sub>, 40 mM KCl, and 20 mM 2-ME. Moloney-Murine Leukemia Virus (Bethesda Research Laboratories (BRL), Gaithersburg, MD) Reverse transcriptase, 26 units, was added and the solution was incubated for 1 hour at 40°C. The resultant first strand cDNA was phenol extracted, ethanol precipitated and then used in the polymerase chain



reaction (PCR) procedures described below for amplification of heavy and light chain sequences.

Primers used for amplification of heavy chain Fd fragments for construction of the M13IX30 library is shown in Table I. Amplification was performed in eight separate reactions, as described by Saiki et al., Science, 239:487-491 (1988), which is incorporated herein by reference, each reaction containing one of the 5' primers (primers 2 to,9; SEQ ID NOS: 7 through 14, respectively) and one of the 3' primers (primer 12; SEQ ID NO: 17) listed in Table I. The remaining 5' primers, used for amplification in a single reaction, are either a degenerate primer (primer 1; SEQ ID NO: 6) or a primer that incorporates inosine at four degenerate positions (primer 10; SEQ ID NO: 15). The remaining 3' primer (primer 11; SEQ ID NO: 16) was used to construct Fv fragments. The underlined portion of the 5' primers incorporates an Xho I site and that of the 3' primer an Spe I restriction site for cloning the amplified fragments into the M13IX30 vector in a predetermined reading frame for expression.

TABLE I  
HEAVY CHAIN PRIMERS

25	1) 5'- AGGT <sup>CC G G</sup> A CT <u>CTCGAGTC</u> <sup>T</sup> GG - 3' GA A T                   A
	2) 5' - AGGTCCAGCTGCTCGAGTCTGG - 3'
	3) 5' - AGGTCCAGCTGCTCGAGTCAGG - 3'
	4) 5' - AGGTCCAGCTTCTCGAGTCTGG - 3'
	5) 5' - AGGTCCAGCTTCTCGAGTCAGG - 3'
30	6) 5' - AGGTCCAAGCTGCTCGAGTCTGG - 3'
	7) 5' - AGGTCCAAGCTGCTCGAGTCAGG - 3'
	8) 5' - AGGTCCAAGCTTCTCGAGTCTGG - 3'

9) 5' - AGGTCCAACTTCTCGAGTCAGG - 3'

5      11)      5' - CTATTAACTAGTAACGGTAACAGT -  
                                 GGTGCCTTGCCCCA - 3'

Primers used for amplification of mouse kappa light chain sequences for construction of the M13IX11 library are shown in Table II. These primers were chosen to contain restriction sites which were compatible with vector and not present in the conserved sequences of the mouse light chain mRNA. Amplification was performed as described above in five separate reactions, each containing one of the 5' primers (primers 3 to 7; SEQ ID NOS: 20 through 24, respectively) and one of the 3' primers (primer 9; SEQ ID NO: 26) listed in Table II. The remaining 3' primer (primer 8; SEQ ID NO: 25) was used to construct Fv fragments. The underlined portion of the 5' primers depicts a Sac I restriction site and that of the 3' primers an Xba I restriction site for cloning of the amplified fragments into the M13IX11 vector in a predetermined reading frame for expression.

TABLE II  
LIGHT CHAIN PRIMERS

1) 5' - CCAGTTCCGAGCTCGTTGTGACTCAGGAATCT - 3'

2) 5' - CCAGTTCCGAGCTCGTGTTGACGCAGCCGCCC - 3'

3) 5' - CCAGTTCCGAGCTCGTGCTCAGCCAGTCTCCA - 3'

30 4) 5' - CCAGTTCCGAGCTCCAGATGACCCAGTCTCCA - 3'

5) 5' - CCAGATGTGAGCTCGTGATGACCCAGACTCCA - 3'

6) 5' - CCAGATGTGAGCTCGTCATGACCCAGTCTCCA - 3'

7) 5' - CCAGTTCCGAGCTCGTGATGACACAGTCTCCA - 3'

8) 5' - GCAGCATTCTAGAGTTTTAGCTCCAGCTTGCC - 3'

35 9) 5' - GCGCCGTCTAGAATTAACAATCATTTCCTGTTGAA - 3'

PCR amplification for heavy and light chain fragments was performed in a 100  $\mu$ l reaction mixture containing the above described products of the reverse transcription reaction ( $\approx 5\mu$ g of the cDNA-RNA hybrid), 300 nmol of 3' V<sub>H</sub> primer (primer 12, Table I; SEQ ID NO: 17), and one of the 5' V<sub>H</sub> primers (primers 2-9, Table I; SEQ ID NOS: 7 through 14, respectively) for heavy chain amplification, or, 300 nmol of 3' V<sub>L</sub> primer (primer 9, Table II; SEQ ID NO: 26), and one of the 5' V<sub>L</sub> primers (primers 3-7, Table II; SEQ ID NOS: 20 through 24, respectively) for each light chain amplification, a mixture of dNTPs at 200 mM, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 15 mM MgCl<sub>2</sub>, 0.1% gelatin, and 2 units of *Thermus aquaticus* DNA polymerase. The reaction mixture was overlaid with mineral oil and subjected to 40 cycles of amplification. Each amplification cycle involved denaturation at 92°C for 1 minute, annealing at 52°C for 2 minutes, and elongation at 72°C for 1.5 minutes. The amplified samples were extracted twice with phenol/CHCl<sub>3</sub> and once with CHCl<sub>3</sub>, ethanol-precipitated, and stored at -70°C in 10 mM Tris-HCl, pH 7.5 1 mM EDTA. The resultant products were used in constructing the M13IX30 and M13IX11 libraries (see below).

#### Vector Construction

Two M13-based vectors, M13IX30 (SEQ ID NO: 1) and M13IX11 (SEQ ID NO: 2), were constructed for the cloning and propagation of Hc and Lc populations of antibody fragments, respectively. The vectors were constructed to facilitate the random joining and subsequent surface expression of antibody fragment populations.

M13IX30 (SEQ ID NO: 1), or the Hc vector, was constructed to harbor diverse populations of Hc antibody fragments. M13mp19 (Pharmacia, Piscataway, NJ) was the starting vector. This vector was modified to contain, in addition to the encoded wild type M13 gene VIII: (1) a

pseudo-wild type gene VIII sequence with an amber stop codon between it and the restriction sites for cloning oligonucleotides; (2) Stu I restriction site for insertion of sequences by hybridization and, Spe I and Xho I restriction sites in-frame with the pseudo-wild type gene VIII for cloning Hc sequences; (3) sequences necessary for expression, such as a promoter, signal sequence and translation initiation signals; (4) two pairs of Hind III-Mlu I sites for random joining of Hc and Lc vector portions, and (5) various other mutations to remove redundant restriction sites and the amino terminal portion of Lac Z.

Construction of M13IX30 was performed in four steps. In the first step, an M13-based vector containing the pseudo gVIII and various other mutations was constructed, M13IX01F. The second step involved the construction of a small cloning site in a separate M13mp18 vector to yield M13IX03. This vector was then expanded to contain expression sequences and restriction sites for Hc sequences to form M13IX04B. The fourth and final step involved the incorporation of the newly constructed sequences in M13IX04B into M13IX01F to yield M13IX30.

Construction of M13IX01F first involved the generation of a pseudo wild-type gVIII sequence for surface expression of antibody fragments. The pseudo-wild type gene encodes the identical amino acid sequence as that of the wild type gene; however, the nucleotide sequence has been altered so that only 63% identity exists between this gene and the encoded wild type gene VIII. Modification of the gene VIII nucleotide sequence used for surface expression reduces the possibility of homologous recombination with the wild type gene VIII contained on the same vector. Additionally, the wild type M13 gene VIII was retained in the vector system to ensure that at least some functional, non-fusion coat protein would be produced. The inclusion of wild type gene

VIII facilitates the growth of phage under conditions where there is surface expression of the polypeptides and therefore reduces the possibility of non-viable phage production from the fusion genes.

- 5       The pseudo-wild type gene VIII was constructed by chemically synthesizing a series of oligonucleotides which encode both strands of the gene. The oligonucleotides are presented in Table III.

TABLE IIIPseudo-Wild Type Gene VIII Oligonucleotide Series

	<u>Top Strand</u> <u>Oligonucleotides</u>	<u>Sequence (5' to 3')</u>
5	VIII 03	GATCC TAG GCT GAA GGC GAT GAC CCT GCT AAG GCT GC
	VIII 04	A TTC AAT AGT TTA CAG GCA AGT GCT ACT GAG TAC
10	VIII 05	A TT GGC TAC GCT TGG GCT ATG GTA GTA GTT ATA GTT
	VIII 06	GGT GCT ACC ATA GGG ATT AAA TTA TTC AAA AAG TT
15	VIII 07	T ACG AGC AAG GCT TCT TA
	<u>Bottom Strand</u> <u>Oligonucleotides</u>	
20	VIII 08	AGC TTA AGA AGC CTT GCT CGT AAA CTT TTT GAA TAA TTT
	VIII 09	AAT CCC TAT GGT AGC ACC AAC TAT AAC TAC TAC CAT
25	VIII 10	AGC CCA AGC GTA GCC AAT GTA CTC AGT AGC ACT TG
	VIII 11	C CTG TAA ACT ATT GAA TGC AGC CTT AGC AGG GTC
	VIII 12	ATC GCC TTC AGC CTA G

Except for the terminal oligonucleotides VIII 03 (SEQ  
 30 ID NO: 27) and VIII 08 (SEQ ID NO: 32), the above  
 oligonucleotides (oligonucleotides VIII 04-07 (SEQ ID NOS:  
 28 through 31, respectively) and VIII 09-12 (SEQ ID NOS: 33

through 36, respectively)) were mixed at 200 ng each in 10  $\mu$ l final volume, phosphorylated with T4 polynucleotide Kinase (Pharmacia) and ~~1 mM~~ ATP at 37°C for 1 hour, heated to 70°C for 5 minutes, and annealed into double-stranded  
5 form by heating to 65°C for 3 minutes, followed by cooling to room temperature over a period of 30 minutes. The reactions were treated with 1.0 U of T4 DNA ligase (BRL) and 1 mM ATP at room temperature for 1 hour, followed by heating to 70°C for 5 minutes. Terminal oligonucleotides  
10 were then annealed to the ligated oligonucleotides. The annealed and ligated oligonucleotides yielded a double-stranded DNA flanked by a Bam HI site at its 5' end and by a Hind III site at its 3' end. A translational stop codon (amber) immediately follows the Bam HI site. The gene VIII  
15 sequence begins with the codon GAA (Glu) two codons 3' to the stop codon. The double-stranded insert was cloned in frame with the Eco RI and Sac I sites within the M13 polylinker. To do so, M13mp19 was digested with Bam HI (New England Biolabs, Beverly, MA) and Hind III (New  
20 England Biolabs) and combined at a molar ratio of 1:10 with the double-stranded insert. The ligations were performed at room temperature overnight in 1X ligase buffer (50 mM Tris-HCl, pH 7.8, 10 mM MgCl<sub>2</sub>, 20 mM DTT, 1 mM ATP, 50  $\mu$ g/ml BSA) containing 1.0 U of T4 DNA ligase (New England  
25 Biolabs). The ligation mixture was transformed into a host and screened for positive clones using standard procedures in the art.

Several mutations were generated within the construct to yield functional M13IX01F. The mutations were generated  
30 using the method of Kunkel et al., Meth. Enzymol. 154:367-382 (1987), which is incorporated herein by reference, for site-directed mutagenesis. The reagents, strains and protocols were obtained from a Bio Rad Mutagenesis kit (Bio Rad, Richmond, CA) and mutagenesis was performed as  
35 recommended by the manufacturer.

Two Fok I sites were removed from the vector as well as the Hind III site at the end of the pseudo gene VIII sequence using the mutant oligonucleotides 5'-CATTTTTGCAGATGGCTTAGA-3' (SEQ ID NO: 37) and 5'-TAGCATTAACGTCCAATA-3' (SEQ ID NO: 38). New Hind III and Mlu I sites were also introduced at position 3919 and 3951 of M13IX01F. The oligonucleotides used for this mutagenesis had the sequences 5'-ATATATTTTAGTAAGCTTCATCTTCT-3' (SEQ ID NO: 39) and 5'-GACAAAGAACGCGTGAAACTTT-3' (SEQ ID NO: 40), respectively. The amino terminal portion of Lac Z was deleted by oligonucleotide-directed mutagenesis using the mutant oligonucleotide 5'-GCGGGCTCTTCGCTATTGCTTAAGAAGCCTTGCT-3' (SEQ ID NO: 41). In constructing the above mutations, all changes made in a M13 coding region were performed such that the amino acid sequence remained unaltered. The resultant vector, M13IX01F, was used in the final step to construct M13IX30 (see below).

In the second step, M13mp18 was mutated to remove the 5' end of Lac Z up to the Lac i binding site and including the Lac Z ribosome binding site and start codon. Additionally, the polylinker was removed and a Mlu I site was introduced in the coding region of Lac Z. A single oligonucleotide was used for these mutagenesis and had the sequence 5'-AAACGACGGCCAGTGCCAAGTGACGCGTGTGAAATTGTTATCC-3' (SEQ ID NO: 42). Restriction enzyme sites for Hind III and Eco RI were introduced downstream of the Mlu I site using the oligonucleotide 5'-GGCGAAAGGGAATTCTGCAAGGCGATTAAGCTTGGGTAACGCC-3' (SEQ ID NO. 43). These modifications of M13mp18 yielded the precursor vector M13IX03.

The expression sequences and cloning sites were introduced into M13IX03 by chemically synthesizing a series of oligonucleotides which encode both strands of the desired sequence. The oligonucleotides are presented in Table IV.



TABLE IV  
M13IX30 Oligonucleotide Series

<u>Top Strand</u> <u>Oligonucleotides</u>		<u>Sequence (5' to 3')</u>
5	084	GGCGTTACCCAAGCTTTGTACATGGAGAAAATAAAG
	027	TGAAACAAAGCACTATTGCACTGGCACTCTTACCGT TACCGT
	028	TACTGTTTACCCCTGTGACAAAAGCCGCCAGGTCC AGCTGC
10	029	TCGAGTCAGGCCTATTGTGCCCAGGGATTGTACTAG TGGATCCG
<u>Bottom</u> <u>Oligonucleotides</u>		<u>Sequence (5' to 3')</u>
	085	TGGCGAAAGGGAATTCCGATCCACTAGTACAATCCCTG
15	031	GGCACAATAGGCCTGACTCGAGCAGCTGGACCAGGGCG GCTT
	032	TTGTCACAGGGGTAAACAGTAACGGTAACGGTAAGTGT GCCA
20	033	GTGCAATAGTGCTTTGTTTCACTTTATTTTCTCCATGT ACAA

The above oligonucleotides of Table IV, except for the terminal oligonucleotides 084 (SEQ ID NO: 44) and 085 (SEQ ID NO: 48), were mixed, phosphorylated, annealed and ligated to form a double-stranded insert as described in Example I. However, instead of cloning directly into the intermediate vector the insert was first amplified by PCR. The terminal oligonucleotides were used as primers for PCR. Oligonucleotide 084 (SEQ ID NO: 44) contains a Hind III site, 10 nucleotides internal to its 5' end and oligonucleotide 085 (SEQ ID NO: 48) has an Eco RI site at its 5' end. Following amplification, the products were restricted with Hind III and Eco RI and ligated, as described in Example I, into the polylinker of M13mp18 digested with the same two enzymes. The resultant double

stranded insert contained a ribosome binding site, a translation initiation codon followed by a leader sequence and three restriction enzyme sites for cloning random oligonucleotides (Xho I, Stu I, Spe I). The intermediate  
5 vector was named M13IX04.

During cloning of the double-stranded insert, it was found that one of the GCC codons in oligonucleotides 028 and its complement in 031 was deleted. Since this deletion did not affect function, the final construct is missing one  
10 of the two GCC codons. Additionally, oligonucleotide 032 (SEQ ID NO: 50) contained a GTG codon where a GAG codon was needed. Mutagenesis was performed using the oligonucleotide 5'-TAACGGTAAGAGTGCCAGTGC-3' (SEQ ID NO: 52) to convert the codon to the desired sequence. The  
15 resultant vector is named M13IX04B.

The third step in constructing M13IX30 involved inserting the expression and cloning sequences from M13IX04B upstream of the pseudo wild-type gVIII in M13IX01F. This was accomplished by digesting M13IX04B with  
20 Dra III and Bam HI and gel isolating the 700 base pair insert containing the sequences of interest. M13IX01F was likewise digested with Dra III and Bam HI. The insert was combined with the double digested vector at a molar ratio of 1:1 and ligated as described in Example I. The sequence  
25 of the final construct M13IX30, is shown in Figure 2 (SEQ ID NO: 1). Figure 1A also shows M13IX30 where each of the elements necessary for surface expression of Hc fragments is marked. It should be noted during modification of the vectors, certain sequences differed from the published  
30 sequence of M13mp18. The new sequences are incorporated into the sequences recorded herein.

M13IX11 (SEQ ID NO: 2), or the Lc vector, was constructed to harbor diverse populations of Lc antibody fragments. This vector was also constructed from M13mp19

and contains: (1) sequences necessary for expression, such as a promoter, signal sequence and translation initiation signals; (2) ~~Eco RV~~ restriction site for insertion of sequences by hybridization and Sac I and Xba I restriction sites for cloning of Lc sequences; (3) two pairs of Hind III-Mlu I sites for random joining of Hc and Lc vector portions, and (4) various other mutation to remove redundant restriction sites.

The expression, translation initiation signals, cloning sites, and one of the Mlu I sites were constructed by annealing of overlapping oligonucleotides as described above to produce a double-stranded insert containing a 5' Eco RI site and a 3' Hind III site. The overlapping oligonucleotides are shown in Table V and were ligated as a double-stranded insert between the Eco RI and Hind III sites of M13mp18 as described for the expression sequences inserted into M13IX03. The ribosome binding site (AGGAGAC) is located in oligonucleotide 015 and the translation initiation codon (ATG) is the first three nucleotides of oligonucleotide 016 (SEQ ID NO: 55).

TABLE V

Oligonucleotide Series for Construction of  
Translation Signals in M13IX11

	<u>Oligonucleotide</u>	<u>Sequence (5' to 3')</u>
5	082	CACC TTCATG AATTC GGC AAG GAGACA GTCAT
	015	AATT C GCC AAG GAG ACA GTC AT
	016	AATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TT
10	017	ATTA CTC GCT GCC CAA CCA GCC ATG GCC GAG CTC GTG AT
	018	GACC CAG ACT CCA GATATC CAA CAG GAA TGA GTG TTA AT
	019	TCT AGA ACG CGT C
15	083	TTCAGGTTGAAGC TTA CGC GTT CTA GAA TTA ACA CTC ATT CCTGT
	021	TG GAT ATC TGG AGT CTG GGT CAT CAC GAG CTC GGC CAT G
20	022	GC TGG TTG GGC AGC GAG TAA TAA CAA TCC AGC GGC TGC C
	023	GT AGG CAA TAG GTA TTT CAT TAT GAC TGT CCT TGG CG

Oligonucleotide 017 (SEQ ID NO: 56) contained a Sac I  
 25 restriction site 67 nucleotides downstream from the ATG  
 codon. The naturally occurring Eco RI site was removed and  
 new Eco RI and Hind III sites were introduced downstream  
 from the Sac I. Oligonucleotides 5'-  
 TGACTGTCTCCTTGGCGTGTGAAATTGTTA-3' (SEQ ID NO: 63) and 5'-  
 30 TAACACTCATTCGGATGGAATTCTGGAGTCTGGGT-3' (SEQ ID NO: 64)  
 were used to generate each of the mutations, respectively.  
 The Lac Z ribosome binding site was removed when the

original Eco RI site in M13mp19 was mutated. Additionally, when the new Eco RI and Hind III sites were generated, a spontaneous 100 bp deletion was found just 3' to these sites. Since the deletion does not affect the function, it was retained in the final vector.

In addition to the above mutations, a variety of other modifications were made to incorporate or remove certain sequences. The Hind III site used to ligate the double-stranded insert was removed with the oligonucleotide 5'-GCCAGTGCCAAGTGACGCGTTCTA-3' (SEQ ID NO: 65). Second Hind III and Mlu I sites were introduced at positions 3922 and 3952, respectively, using the oligonucleotides 5'-ATATATTTTAGTAAGCTTCATCTTCT-3' (SEQ ID NO: 66) for the Hind III mutagenesis and 5'-GACAAAGAACGCGTGAAAACCTTT-3' (SEQ ID NO: 67) for the Mlu I mutagenesis. Again, mutations within the coding region did not alter the amino acid sequence.

The sequence of the resultant vector, M13IX11, is shown in Figure 3 (SEQ ID NO: 2). Figure 1B also shows M13IX11 where each of the elements necessary for producing a surface expression library between Lc fragments is marked.

#### Library Construction

Each population of Hc and Lc sequences synthesized by PCR above are separately cloned into M13IX30 and M13IX11, respectively, to create Hc and Lc libraries.

The Hc and Lc products (5  $\mu$ g) are mixed, ethanol precipitated and resuspended in 20  $\mu$ l of NaOAc buffer (33 mM Tris acetate, pH 7.9, 10 mM Mg-acetate, 66 mM K-acetate, 0.5 mM DTT). Five units of T4 DNA polymerase is added and the reactions incubated at 30°C for 5 minutes to remove 3' termini by exonuclease digestion. Reactions are stopped by heating at 70°C for 5 minutes. M13IX30 is digested with

Stu I and M13IX11 is digested with Eco RV. Both vectors are treated with T4 DNA polymerase as described above and combined with the appropriate PCR products at a 1:1 molar ratio at 10 ng/ $\mu$ l to anneal in the above buffer at room temperature overnight. DNA from each annealing is electroporated into MK30-3 (Boehringer, Indianapolis, IN), as described below, to generate the Hc and Lc libraries.

E. coli MK30-3 is electroporated as described by Smith et al., Focus 12:38-40 (1990) which is incorporated herein by reference. The cells are prepared by inoculating a fresh colony of MK30-3 into 5 mls of SOB without magnesium (20 g bacto-tryptone, 5 g bacto-yeast extract, 0.584 g NaCl, 0.186 g KCl, dH<sub>2</sub>O to 1,000 mls) and grown with vigorous aeration overnight at 37°C. SOB without magnesium (500 ml) is inoculated at 1:1000 with the overnight culture and grown with vigorous aeration at 37°C until the OD<sub>550</sub> is 0.8 (about 2 to 3 h). The cells are harvested by centrifugation at 5,000 rpm (2,600 x g) in a GS3 rotor (Sorvall, Newtown, CT) at 4°C for 10 minutes, resuspended in 500 ml of ice-cold 10% (v/v) sterile glycerol, centrifuged and resuspended a second time in the same manner. After a third centrifugation, the cells are resuspended in 10% sterile glycerol at a final volume of about 2 ml, such that the OD<sub>550</sub> of the suspension was 200 to 300. Usually, resuspension is achieved in the 10% glycerol that remained in the bottle after pouring off the supernate. Cells are frozen in 40  $\mu$ l aliquots in microcentrifuge tubes using a dry ice-ethanol bath and stored frozen at -70°C.

Frozen cells are electroporated by thawing slowly on ice before use and mixing with about 10 pg to 500 ng of vector per 40  $\mu$ l of cell suspension. A 40  $\mu$ l aliquot is placed in an 0.1 cm electroporation chamber (Bio-Rad, Richmond, CA) and pulsed once at 0°C using 4 k $\Omega$  parallel resistor 25  $\mu$ F, 1.88 KV, which gives a pulse length ( $\tau$ ) of

4 ms. A 10  $\mu$ l aliquot of the pulsed cells are diluted into 1 ml SOC (98 mls SOB plus 1 ml of 2 M  $MgCl_2$  and 1 ml of 2 M glucose) in a 12- x 75-mm culture tube, and the culture is shaken at 37°C for 1 hour prior to culturing in selective media, (see below).

Each of the libraries are cultured using methods known to one skilled in the art. Such methods can be found in Sanbrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989, and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, New York, 1989, both of which are incorporated herein by reference. Briefly, the above 1 ml library cultures are grown up by diluting 50-fold into 2XYT media (16 g tryptone, 10 g yeast extract, 5 g NaCl) and culturing at 37°C for 5-8 hours. The bacteria are pelleted by centrifugation at 10,000 x g. The supernatant containing phage is transferred to a sterile tube and stored at 4°C.

Double strand vector DNA containing Hc and Lc antibody fragments are isolated from the cell pellet of each library. Briefly, the pellet is washed in TE (10 mM Tris, pH 8.0, 1 mM EDTA) and recollected by centrifugation at 7,000 rpm for 5' in a Sorval centrifuge (Newtown, CT). Pellets are resuspended in 6 mls of 10% Sucrose, 50 mM Tris, pH 8.0. 3.0 ml of 10 mg/ $\mu$ l lysozyme is added and incubated on ice for 20 minutes. 12 mls of 0.2 M NaOH, 1% SDS is added followed by 10 minutes on ice. The suspensions are then incubated on ice for 20 minutes after addition of 7.5 mls of 3 M NaOAc, pH 4.6. The samples are centrifuged at 15,000 rpm for 15 minutes at 4°C, RNased and extracted with phenol/chloroform, followed by ethanol precipitation. The pellets are resuspended, weighed and an equal weight of  $CsCl_2$  is dissolved into each tube until a density of 1.60 g/ml is achieved. EtBr is added to 600  $\mu$ g/ml and the double-stranded DNA is isolated by

equilibrium centrifugation in a TV-1665 rotor (Sorval) at 50,000 rpm for 6 hours. These DNAs from each right and left half sublibrary are used to generate forty libraries in which the right and left halves of the randomized oligonucleotides have been randomly joined together.

The surface expression library is formed by the random joining of the Hc containing portion of M13IX30 with the Lc containing portion of M13IX11. The DNAs isolated from each library was digested separately with an excess amount of restriction enzyme. The Lc population (5  $\mu$ g) is digested with Hind III. The Hc (5  $\mu$ g) population is digested with Mlu I. The reactions are stopped by phenol/chloroform extraction followed by ethanol precipitation. The pellets are washed in 70% ethanol and resuspended in 20  $\mu$ l of NaOAc buffer. Five units of T4 DNA polymerase (Pharmacia) is added and the reactions incubated at 30°C for 5 minutes. Reactions are stopped by heating at 70°C for 5 minutes. The Hc and Lc DNAs are mixed to a final concentration of 10 ng each vector/ $\mu$ l and allowed to anneal at room temperature overnight. The mixture is electroporated into MK30-3 cells as described above.

#### Screening of Surface Expression Libraries

Purified phage are prepared from 50 ml liquid cultures of XL1 Blue<sup>TM</sup> cells (Stratagene, La Jolla, CA) which had been infected at a m.o.i. of 10 from the phage stocks stored at 4°C. The cultures are induced with 2 mM IPTG. Supernatants are cleared by two centrifugations, and the phage are precipitated by adding 1/7.5 volumes of PEG solution (25% PEG-8000, 2.5 M NaCl), followed by incubation at 4°C overnight. The precipitate is recovered by centrifugation for 90 minutes at 10,000 x g. Phage pellets are resuspended in 25 ml of 0.01 M Tris-HCl, pH 7.6, 1.0 mM EDTA, and 0.1% Sarkosyl and then shaken slowly at room temperature for 30 minutes. The solutions are adjusted to



0.5 M NaCl and to a final concentration of 5% polyethylene glycol. After 2 hours at 4°C, the precipitates containing the phage are recovered by centrifugation for 1 hour at 15,000 X g. The precipitates are resuspended in 10 ml of  
5 NET buffer (0.1 M NaCl, 1.0 mM EDTA, and 0.01 M Tris-HCl, pH 7.6), mixed well, and the phage repelleted by centrifugation at 170,000 X g for 3 hours. The phage pellets are resuspended overnight in 2 ml of NET buffer and subjected to cesium chloride centrifugation for 18 hours at  
10 110,000 X g (3.86 g of cesium chloride in 10 ml of buffer). Phage bands are collected, diluted 7-fold with NET buffer, recentrifuged at 170,000 X g for 3 hours, resuspended, and stored at 4°C in 0.3 ml of NET buffer containing 0.1 mM sodium azide.

15 The BDP used for panning on streptavidin coated dishes is first biotinylated and then absorbed against UV-inactivated blocking phage (see below). The biotinylating reagents are dissolved in dimethylformamide at a ratio of 2.4 mg solid NHS-SS-Biotin (sulfosuccinimidyl 2-  
20 (biotinamido)ethyl-1,3'-dithiopropionate; Pierce, Rockford, IL) to 1 ml solvent and used as recommended by the manufacturer. Small-scale reactions are accomplished by mixing 1 µl dissolved reagent with 43 µl of 1 mg/ml BDP diluted in sterile bicarbonate buffer (0.1 M NaHCO<sub>3</sub>, pH  
25 8.6). After 2 hours at 25°C, residual biotinylating reagent is reacted with 500 µl 1 M ethanolamine (pH adjusted to 9 with HCl) for an additional 2 hours. The entire sample is diluted with 1 ml TBS containing 1 mg/ml BSA, concentrated to about 50 µl on a Centricon 30 ultra-  
30 filter (Amicon), and washed on the same filter three times with 2 ml TBS and once with 1 ml TBS containing 0.02% NaN<sub>3</sub> and 7 x 10<sup>12</sup> UV-inactivated blocking phage (see below); the final retentate (60-80 µl) is stored at 4 °C. BDP biotinylated with the NHS-SS-Biotin reagent is linked to  
35 biotin via a disulfide-containing chain.

UV-irradiated M13 phage are used for blocking any biotinylated BDP which fortuitously binds filamentous phage in general. M13mp8 (Messing and Vieira, Gene 19: 262-276 (1982), which is incorporated herein by reference) is  
5 chosen because it carries two amber mutations, which ensure that the few phage surviving irradiation will not grow in the sup 0 strains used to titer the surface expression library. A 5 ml sample containing  $5 \times 10^{13}$  M13mp8 phage, purified as described above, is placed in a small petri  
10 plate and irradiated with a germicidal lamp at a distance of two feet for 7 minutes (flux  $150 \mu\text{W}/\text{cm}^2$ ).  $\text{NaN}_3$  is added to 0.02% and phage particles concentrated to  $10^{14}$  particles/ml on a Centricon 30-kDa ultrafilter (Amicon).

For panning, polystyrene petri plates (60 x 15 mm) are  
15 incubated with 1 ml of 1 mg/ml of streptavidin (BRL) in 0.1 M  $\text{NaHCO}_3$  pH 8.6-0.02%  $\text{NaN}_3$  in a small, air-tight plastic box overnight in a cold room. The next day streptavidin is removed and replaced with at least 10 ml blocking solution (29 mg/ml of BSA; 3  $\mu\text{g}/\text{ml}$  of streptavidin; 0.1 M  $\text{NaHCO}_3$  pH  
20 8.6-0.02%  $\text{NaN}_3$ ) and incubated at least 1 hour at room temperature. The blocking solution is removed and plates are washed rapidly three times with Tris buffered saline containing 0.5% Tween 20 (TBS-0.5% Tween 20).

Selection of phage expressing antibody fragments which  
25 bind BDP is performed with 5  $\mu\text{l}$  (2.7  $\mu\text{g}$  BDP) of blocked biotinylated BDP reacted with a 50  $\mu\text{l}$  portion of the library. Each mixture is incubated overnight at  $4^\circ\text{C}$ , diluted with 1 ml TBS-0.5% Tween 20, and transferred to a streptavidin-coated petri plate prepared as described  
30 above. After rocking 10 minutes at room temperature, unbound phage are removed and plates washed ten times with TBS-0.5% Tween 20 over a period of 30-90 minutes. Bound phage are eluted from plates with 800  $\mu\text{l}$  sterile elution buffer (1 mg/ml BSA, 0.1 M HCl, pH adjusted to 2.2 with  
35 glycerol) for 15 minutes and eluates neutralized with 48  $\mu\text{l}$

2 M Tris (pH unadjusted). A 20  $\mu$ l portion of each eluate is titered on MK30-3 concentrated cells with dilutions of input phage.

A second round of panning is performed by treating 750  $\mu$ l of first eluate from the library with 5 mM DTT for 10 minutes to break disulfide bonds linking biotin groups to residual biotinylated binding proteins. The treated eluate is concentrated on a Centricon 30 ultrafilter (Amicon), washed three times with TBS-0.5% Tween 20, and concentrated to a final volume of about 50  $\mu$ l. Final retentate is transferred to a tube containing 5.0  $\mu$ l (2.7  $\mu$ g BDP) blocked biotinylated BDP and incubated overnight. The solution is diluted with 1 ml TBS-0.5% Tween 20, panned, and eluted as described above on fresh streptavidin-coated petri plates. The entire second eluate (800  $\mu$ l) is neutralized with 48  $\mu$ l 2 M Tris, and 20  $\mu$ l is titered simultaneously with the first eluate and dilutions of the input phage. If necessary, further rounds of panning can be performed to obtain homogeneous populations of phage. Additionally, phage can be plaque purified if reagents are available for detection.

#### Template Preparation and Sequencing

Templates are prepared for sequencing by inoculating a 1 ml culture of 2XYT containing a 1:100 dilution of an overnight culture of XL1 with an individual plaque from the purified population. The plaques are picked using a sterile toothpick. The culture is incubated at 37°C for 5-6 hours with shaking and then transferred to a 1.5 ml microfuge tube. 200  $\mu$ l of PEG solution is added, followed by vortexing and placed on ice for 10 minutes. The phage precipitate is recovered by centrifugation in a microfuge at 12,000 x g for 5 minutes. The supernatant is discarded and the pellet is resuspended in 230  $\mu$ l of TE (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) by gently pipeting with a yellow

pipet tip. Phenol (200  $\mu$ l) is added, followed by a brief vortex and microfuged to separate the phases. The aqueous phase is transferred to a separate tube and extracted with 200  $\mu$ l of phenol/chloroform (1:1) as described above for the phenol extraction. A 0.1 volume of 3 M NaOAc is added, followed by addition of 2.5 volumes of ethanol and precipitated at  $-20^{\circ}\text{C}$  for 20 minutes. The precipitated templates are recovered by centrifugation in a microfuge at 12,000 x g for 8 minutes. The pellet is washed in 70% ethanol, dried and resuspended in 25  $\mu$ l TE. Sequencing was performed using a Sequenase<sup>TM</sup> sequencing kit following the protocol supplied by the manufacturer (U.S. Biochemical, Cleveland, OH).

#### EXAMPLE II

##### Cloning of Heavy and Light Chain Sequences Without Restriction Enzyme Digestion

This example shows the simultaneous incorporation of antibody heavy and light chain fragment encoding sequences into a M13IXHL-type vector with the use of restriction endonucleases.

For the simultaneous incorporation of heavy and light chain encoding sequences into a single coexpression vector, a M13IXHL vector was produced that contained heavy and light chain encoding sequences for a mouse monoclonal antibody (DAN-18H4; Biosite, San Diego, CA). The inserted antibody fragment sequences are used as complementary sequences for the hybridization and incorporation of Hc and Lc sequences by site-directed mutagenesis. The genes encoding the heavy and light chain polypeptides were inserted into M13IX30 (SEQ ID NO: 1) and M13IX11 (SEQ ID NO: 2), respectively, and combined into a single surface expression vector as described in Example I. The resultant M13IXHL-type vector is termed M13IX50.

The combinations were performed under conditions that facilitate the formation of one Hc and one Lc vector half into a single circularized vector. Briefly, the overhangs generated between the pairs of restriction sites after  
5 restriction with Mlu I or Hind III and exonuclease digestion are unequal (i.e., 64 nucleotides compared to 32 nucleotides). These unequal lengths result in differential hybridization temperatures for specific annealing of the complementary ends from each vector. The specific  
10 hybridization of each end of each vector half was accomplished by first annealing at 65°C in a small volume (about 100 µg/µl) to form a dimer of one Hc vector half and one Lc vector half. The dimers were circularized by diluting the mixture (to about 20 µg/µl) and lowering the  
15 temperature to about 25-37°C to allow annealing. T4 ligase was present to covalently close the circular vectors.

M13IX50 was modified such that it did not produce a functional polypeptide for the DAN monoclonal antibody. To do this, about eight amino acids were changed within the  
20 variable region of each chain by mutagenesis. The Lc variable region was mutagenized using the oligonucleotide 5'-CTGAACCTGTCTGGGACCACAGTTGATGCTATAGGATCAGATCTAGAATTCATT  
TAGAGACTGGCCTGGCTTCTGC-3' (SEQ ID NO: 68). The Hc sequence was mutagenized with the oligonucleotide 5'-  
25 TCGACCGTTGGTAGGAATAATGCAATTAAATG  
GAGTAGCTCTAAATTCAGAATTCATCTACACCCAGTGCATCCAGTAGCT-3' (SEQ ID NO: 69). An additional mutation was also introduced into M13IX50 to yield the final form of the vector. During construction of an intermediate to M13IX50 (M13IX04  
30 described in Example I), a six nucleotide sequence was duplicated in oligonucleotide 027 and its complement 032. This sequence, 5'TTACCG-3' was deleted by mutagenesis using the oligonucleotide 5'-GGTAAACAGTAACGGTAAGAGTGCCAG-3' (SEQ ID NO: 70). The resultant vector was designated M13IX53.

35 M13IX53 can be produced as a single stranded form and

contains all the functional elements of the previously described M13IXHL vector except that it does not express functional antibody heteromers. The single-stranded vector can be hybridized to populations of single-stranded Hc and  
5 Lc encoding sequences for their incorporation into the vector by mutagenesis. Populations of single-stranded Hc and Lc encoding sequences can be produced by one skilled in the art from the PCR products described in Example I or by other methods known to one skilled in the art using the  
10 primers and teachings described therein. The resultant vectors with Hc and Lc encoding sequences randomly incorporated are propagated and screened for desired binding specificities as described in Example I.

Other vectors similar to M13IX53 and the vectors it's  
15 derived from, M13IX11 and M13IX30, have also been produced for the incorporation of Hc and Lc encoding sequences without restriction. In contrast to M13IX53, these vectors contain human antibody sequences for the efficient hybridization and incorporation of populations of human Hc  
20 and Lc sequences. These vectors are briefly described below. The starting vectors were either the Hc vector (M13IX30) or the Lc vector (M13IX11) previously described.

M13IX32 was generated from M13IX30 by removing the six nucleotide redundant sequence 5'-TTACCG-3' described above  
25 and mutation of the leader sequence to increase secretion of the product. The oligonucleotide used to remove the redundant sequence is the same as that given above. The mutation in the leader sequence was generated using the oligonucleotide 5'GGGCTTTTGCCACAGGGGT-3'. This mutagenesis  
30 resulted in the A residue at position 6353 of M13IX30 being changed to a G residue.

A decapeptide tag for affinity purification of antibody fragments was incorporated in the proper reading frame at the carboxy-terminal end of the Hc expression site

in M13IX32. The oligonucleotide used for this mutagenesis was 5'-CGCCTT CAGCCTAAGAAGCGTAGTCCGGAACGTCGTACGGGTAGGATCCA CTAG-3' (SEQ ID NO: 71). The resultant vector was designated M13IX33. Modifications to this or other vectors  
5 are envisioned which include various features known to one skilled in the art. For example, a peptidase cleavage site can be incorporated following the decapeptide tag which allows the antibody to be cleaved from the gene VIII portion of the fusion protein.

10 M13IX34 (SEQ ID NO: 3) was created from M13IX33 by cloning in the gene encoding a human IgG1 heavy chain. The reading frame of the variable region was changed and a stop codon was introduced to ensure that a functional polypeptide would not be produced. The oligonucleotide  
15 used for the mutagenesis of the variable region was 5'-CACCGGTTCTGGGGAATTAGTCTTGACCAGGCAGCCCAGGGC-3' (SEQ ID NO: 72). The complete nucleotide sequence of this vector is shown in Figure 4 (SEQ ID NO: 3).

Several vectors of the M13IX11 series were also  
20 generated to contain similar modifications as that described for the vectors M13IX53 and M13IX34. The promoter region in M13IX11 was mutated to conform to the 35 consensus sequence to generate M13IX12. The oligonucleotide used for this mutagenesis was 5'-ATTCCACAC  
25 ATTATACGAGCCGGAAGCATAAAGTGTCAAGCCTGGGGTGCC-3' (SEQ ID NO: 73). A human kappa light chain sequence was cloned into M13IX12 and the variable region subsequently deleted to generate M13IX13 (SEQ ID NO: 4). The complete nucleotide sequence of this vector is shown in Figure 5 (SEQ ID NO:  
30 4). A similar vector, designated M13IX14, was also generated in which the human lambda light chain was inserted into M13IX12 followed by deletion of the variable region. The oligonucleotides used for the variable region deletion of M13IX13 and M13IX14 were 5'-CTG  
35 CTCATCAGATGGCGGGAAGAGCTCGGCCATGGCTGGTTG-3' (SEQ ID NO: 74)

and 5'-GAACAGAGT GACCGAGGGGGCGAGCTCGGCCATGGCTGGTTG-3' (SEQ ID NO: 75), respectively.

The Hc and Lc vectors or modified forms thereof can be combined using the methods described in Example I to produce a single vector similar to M13IX53 that allows the efficient incorporation of human Hc and Lc encoding sequences by mutagenesis. An example of such a vector is the combination of M13IX13 with M13IX34. The complete nucleotide sequence of this vector, M13IX60, is shown in Figure 6 (SEQ ID NO: 5).

Additional modifications to any of the previously described vectors can also be performed to generate vectors which allow the efficient incorporation and surface expression of Hc and Lc sequences. For example, to alleviate the use of uracil selection against wild-type template during mutagenesis procedures, the variable region locations within the vectors can be substituted by a set of palindromic restriction enzyme sites (i.e., two similar sites in opposite orientation). The palindromic sites will loop out and hybridize together during the mutagenesis and thus form a double-stranded substrate for restriction endonuclease digestion. Cleavage of the site results in the destruction of the wild-type template. The variable region of the inserted Hc or Lc sequences will not be affected since they will be in single stranded form.

Following the methods of Example I, single-stranded Hc or Lc populations can be produced by a variety of methods known to one skilled in the art. For example, the PCR primers described in Example I can be used in asymmetric PCR to generate such populations. Gelfand et al., "PCR Protocols: A Guide to Methods and Applications", Ed by M.A. Innis (1990), which is incorporated herein by reference. Asymmetric PCR is a PCR method that differentially amplifies only a single strand of the double



stranded template. Such differential amplification is accomplished by decreasing the primer amount for the undesirable strand about 10-fold compared to that for the desirable strand. Alternatively, single-stranded populations can be produced from double-stranded PCR products generated as described in Example I except that the primer(s) used to generate the undesirable strand of the double-stranded products is first phosphorylated at its 5' end with a kinase. The resultant products can then, be treated with a 5' to 3' exonuclease, such as lambda exonuclease (BRL, Bethesda, MD) to digest away the unwanted strand.

Single-stranded Hc and Lc populations generated by the methods described above or by others known to one skilled in the art are hybridized to complementary sequences encoded in the previously described vectors. The population of the sequences are subsequently incorporated into a double-stranded form of the vector by polymerase extension of the hybridized templates. Propagation and surface expression of the randomly combined Hc and Lc sequences are performed as described in Example I.

Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: HUSE, WILLIAM D.
- (ii) TITLE OF INVENTION: SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS
- (iii) NUMBER OF SEQUENCES: 75
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
  - (B) STREET: 444 SO. FLOWER STREET, SUITE 200
  - (C) CITY: LOS ANGELES
  - (D) STATE: CALIFORNIA
  - (E) COUNTRY: UNITED STATES
  - (F) ZIP: 90071
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: CAMPBELL, CATHRYN A.
  - (B) REGISTRATION NUMBER: 31,815
  - (C) REFERENCE/DOCKET NUMBER: P31 8882
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 619-535-9001
  - (B) TELEFAX: 619-535-8949

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 7445 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: both
  - (D) TOPOLOGY: circular

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAAT	60
ATAGCTAAAC AGGTTATTGA CCATTTGCCA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTGCGAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCAGACA CCGTACTTTA	180
GTTGCATATT TAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA	240
TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTTG CTTCGGTCT GGTTCGCTTT GAAGCTCGAA TAAAAACGCG ATATTGAAG	360
TCTTTCGGGC TCCTCTTAA TCTTTTGTAT GCAATCCGCT TTGCTTCTGA CTATAATAGT	420

CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTTA CTATTACCCC CTCTGGGAAA ACTTCTTTTG CAAAAGCCTC TCGGTATTTT	600
GGTTTTTATC GTCGCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	660
AATTCCTTTT GCGGTATGT ATCTGCATTA GTTGAATGTG GTATTCCCTAA ATCTCAACTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTC	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCGAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTCAAAG TTGGTCAGTT CGGTCCCTT ATGATTGACC	1080
GTCTGCGCCT CGTTCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCGA CACAATTTAT	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTCGCGC TTGGTATAAT CGCTGGGGGT	1200
CAAAGATGAG TGTTTTAGTG TATCTTTTCG CCTCTTTCGT TTAGGTTGG TGCCTTCGTA	1260
GTGGCATTAC GTATTTTACC CGTTTAATGG AACTTCCTC ATGAAAAAGT CTTTAGTCCT	1320
CAAAGCCTCT GTAGCCGTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT TTAAGTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	1440
TGCGTGGGCG ATGTTGTGTTG TCATTGTGCG CGCAACTATC GGTATCAAGC TGTTTAAGAA	1500
ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1560
TTTTTGAGA TTTTCAACGT GAAAAAATTA TTATTCGAA TTCCTTTAGT TGTTCTTTTC	1620
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AGAAAAATCA	1680
TTTACTAACG TCTGGAAAGA CGACAAAAC TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1740
CTGTGGAATG CTACAGGCGT TGTAATTTGT ACTGGTGACG AACTCAGTG TTACGGTACA	1800
TGGGTTCTTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1920
ATTCGGGGCT ATACTTATAT CAACCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1980
AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT	2040
CAGAATAATA GGTTCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2100
CAAGGCACTG ACCCGGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGGGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTGG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG TGGTCTGGT GCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2400
CATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460

GAAAACGGCG	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCAGCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCCTTTG	GGTATTCGGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACCTTTGT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCAAT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCCTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAGGG	TGTTCACTTA	ATTCTCCCGT	CTAATGCCGT	TCCCTGTTTT	TATGTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACCTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCCGGAGGT	TCGCTAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCGT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTGCGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCCGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTCG	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTATTCA	CTCACATATA	TTGATTATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCCTC	TGCGCGATTT	4320
TGTAACCTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
TACTGTACT	GTATATTCAT	CTGACGTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTT	4440
TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500

TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	4560
TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TTA CTCAAAC	4620
TTTTAAATTT AATAACGTTT GGGCAAAGGA TTTAATACGA GTTGTGCAAT TGTTTGTAAA	4680
GTCTAATACT TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT	4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTTGCC	4800
AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	4860
TTTTTCATTT GCTGCTGGCT CTCAGCGTGG CACTGTTGCA GGCGGTGTTA ATACTGACCG	4920
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTCCGT ATTTTAAATG GCGATGTTTT,	4980
AGGGCTATCA GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG	5040
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTTTAT	5100
TACTGGTCGT GTGACTGGTG AATCTGCCAA TGTAATAAT CCATTTTACA CGATTGAGCG	5160
TCAAATGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTAATATTGT	5220
TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTGATGTTAT	5280
TACTAATCAA AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT	5340
CGGTGGCCTC ACTGATTATA AAAACACTTC TCAAGATTCT GGCGTACCGT TCCTGTCTAA	5400
AATCCCTTTA ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAAGCACGTT	5460
ATACGTGCTC GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATT AAGCGCGCGG	5520
GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCGGCTCCTT	5580
TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC	5640
GGGGGCTCCC TTTAGGGTTC CGATTAGTG CTTTACGGCA CCTCGACCCC AAAAACTTG	5700
ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA	5760
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTCCA AACTGGAACA AACTCAACC	5820
CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTGGAA CCACCATCAA	5880
ACAGGATTTT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG	5940
CCAGGCGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCCT	6000
GGGCCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC	6060
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC	6120
TCACTCATT A GGCACCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGAA	6180
TTGTGAGCGG ATAACAATTT CACACGCGTC ACTTGGCACT GGCCGTGCTT TTACAACGTC	6240
GTGACTGGGA AAACCCTGGC GTTACCCAAG CTTTGTACAT GGAGAAAATA AAGTGAAACA	6300
AAGCACTATT GCACTGGCAC TCTTACGGTT ACGGTTACTG TTTACCCCTG TGACAAAAGC	6360
CGCCCAGGTC CAGCTGCTCG AGTCAGGCCT ATTGTGCCA GGGGATTGTA CTAGTGGATC	6420
CTAGGCTGAA GGCGATGACC CTGCTAAGGC TGCATTCAAT AGTTTACAGG CAAGTGCTAC	6480
TGAGTACATT GGCTACGCTT GGGCTATGGT AGTAGTTATA GTTGGTGCTA CCATAGGGAT	6540

46

TAAATTATTC AAAAAGTTTA CGAGCAAGGC TTCTTAAGCA ATAGCGAAGA GGCCCGCACC	6600
GATCGCCCTT CCCAACAGTT GCGCAGCCTG AATGGCGAAT GCGCCTTTGC CTGGTTTCCG	6660
GCACCAGAAG CCGTGCCGGA AAGCTGGCTG GAGTGCGATC TTCCTGAGGC CGATACGGTC	6720
GTCGTCCCCT CAAACTGGCA GATGCACGGT TACGATGCGC CCATCTACAC CAACGTAACC	6780
TATCCCATTA CGGTCAATCC GCCGTTTGTT CCCACGGAGA ATCCGACGGG TTGTTACTCG	6840
CTCACATTTA ATGTTGATGA AAGCTGGCTA CAGGAAGGCC AGACGCGAAT TATTTTGTAT	6900
GGCGTTCCTA TTGGTTAAAA AATGAGCTGA TTTAACAAAA ATTTAACCGG AATTTTAACA	6960
AAATATTAAC GTTTACAATT TAAATATTTG CTTATACAAT CTCCTGTTT TTGGGGCTTT	7020
TCTGATTATC AACCGGGGTA CATATGATTG ACATGCTAGT TTTACGATT ACGTTCATCG	7080
ATTCTCTTGT TTGCTCCAGA CTCTCAGGCA ATGACCTGAT AGCCTTTGTA GATCTCTCAA	7140
AAATAGCTAC CCTCTCCGGC ATTAATTTAT CAGCTAGAAC GGTGAATAT CATATTGATG	7200
GTGATTGAC TGTCTCCGGC CTTTCTCACC CTTTGAATC TTIACCTACA CATTACTCAG	7260
GCATTGCATT TAAAATATAT GAGGGTTCTA AAAATTTTTA TCCTTGCGTT GAAATAAAGG	7320
CTTCTCCCGC AAAAGTATTA CAGGGTCATA ATGTTTTTGG TACAACCGAT TTAGCTTTAT	7380
GCTCTGAGGC TTTATTGCTT AATTTTGCTA ATTCTTTGCC TTGCCTGTAT GATTATTGG	7440
ACGTT	7445

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7317 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: circular

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2;

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAT	60
ATAGCTAAAC AGGTTATTGA CCATTTGCCA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC AACTGTTACA TGAATGAAA CTTCCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA	240
TCCGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAACGCG ATATTTGAAG	360
TCTTTGCGGC TTCCTCTTAA TCTTTTGTAT GCAATCGGCT TTGCTTCTGA CTATAATAGT	420
CAGGGTAAAG ACCTGATTTT TGATTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCGCGAG TATTGGACGC TATCCAGTCT	540
AAACATTTTA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT	600
JGTTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	660
AATTCCTTTT GCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG	720

ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCCTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCGAATT TACTACTCGT TCTGGTGTTC	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAGG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCTGCGCCT CGTTCGGCT AAGTAACATG GAGCAGGTGG CGGATTTCCA CACAATTTAT	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTCGGCGC TTGGTATAAT CGCTGGGGGT	1200
CAAAGATGAG TGTTTTACTG TATTCTTTCG CCTCTTTCGT TTTAGGTTGG TGCCTTCGTA	1260
GTGGCATTAC GTATTTTACC CGTTTAATGG AAACCTTCCTC ATGAAAAAGT CTTTAGTCTC	1320
CAAAGCCTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT TTAACCTCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	1440
TGCGTGGGCG ATGGTTGTTG TCATTGTCCG CGCAACTATC GGTATCAAGC TGTTTAAGAA	1500
ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1560
TTTTTGGAGA TTTTCAACGT GAAAAAATTA TTATTCGCAA TTCCTTACTG TGTTCCTTTC	1620
TATTCTCACT CCGCTGAAAC TGTGAAAGT TGTTTAGCAA AACCCCATAC AGAAAATTCA	1680
TTTACTAACG TCTGAAAGA CGACAAACT TTAGATCGTT ACGCTAACTA TGAGGCTTGT	1740
CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACCTCAGT TTACGGTACA	1800
TGGGTTCTTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1920
ATTCGGGGCT ATACTTATAT CAACCTCTC GACGGCACTT ATCCGCTGG TACTGAGCAA	1980
AACCCGCTA ATCCTAATCC TTCTCTGAG GAGTCTCAGG CTCTTAATAC TTTCATGTTT	2040
CAGAATAATA GGTTCGGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTACT	2100
CAAGGCACTG ACCCGGTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTCT TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG TGGTCTGGT GCGGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GCGGTTCCG GTGGTGGCTC TGGTCCGGT	2400
GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460
GAAAACGCGC TAGAGTCTGA CGCTAAAGGC AAACCTTGATT CTGTGCTAC TGATTACGGT	2520
GCTGCTATCG ATGGTTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTGCCCCT	2700
TTTGTCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGAGAA AATAAACTTA	2760

TTCCGTGGTG TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG	2820
TTTGCTAACA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCGGT	2880
TATTATTGCG TTTCTCGGT TTCCTTCTGG TAACTTTGTT GGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CTATTTTATT GTTTCTTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTG TGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3060
TTGTTCAGGG TGTTCAAGTT ATTCTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTC	3120
TCTCTGTAAA GGCTGCTATT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTG	3180
ATTGGGATAA ATAATATGGC TGTTTATTTT GTAAGTGGCA AATTAGGCTC TGGAAAGACG	3240
CTCGTTAGCG TTGGTAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	3300
CTTGATTTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT	3360
CTTAGAATAC CGGATAAGCC TTCTATATCT GATTTGCTTG CTATTGGGCG CGGTAATGAT	3420
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGCGGTAC TTGGTTTAAAT	3480
ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCGT	3540
AAATTAGGAT GGGATATTAT TTTTCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGGC	3600
CGTTCTGCAT TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	3660
TTTGTCGGTA CTTTATATTG TCTTATTACT GGCTCGAAAA TGCCTCTGCC TAAATTACAT	3720
GTGGCGGTG TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT	3780
ACTGGTAAGA ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTTCTAG TAATTATGAT	3840
TCCGGTGTAT ATTCTTATTT AACGCCCTAT TTATCAGACG GTCGGTATTT CAAACCATT	3900
AATTTAGGTC AGAAGATGAA GCTTACTAAA ATATATTGTA AAAAGTTTTC ACGCGTTCTT	3960
TGCTCTGCGA TTGGATTGTC ATCAGCATT ACATATAGTT ATATAACCCA ACCTAAGCCG	4020
GAGGTAAAA AGGTAGTCTC TCAGACCTAT GATTTTGATA AATTCACTAT TGAATCTTCT	4080
CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	4140
AGCGACGATT TACAGAAGCA AGGTATTCA CTCACATATA TTGATTATG TACTGTTTCC	4200
ATTAAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGTTT TCTTGATGTT	4260
TGTTTCATCA TCTTCTTTTG CTCAGGTAAT TGAAATGAAT AATTCGCCTC TCGCGGATT	4320
TGTAACCTGG TATTCAAAGC AATCAGGCGA ATCCGTTATT GTTTCTCCCG ATGTAAAAGG	4380
TACTGTTACT GTATATTCAT CTGACGTTAA ACCTGAAAAT CTACGCAATT TCTTTATTT	4440
TGTTTACGTT GCTAATAAAT TTGATATGGT TGGTTCAATT CCTTCGATAA TTCAGAAGTA	4500
TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	4560
TGATAATTCC GTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TTAATCAAAC	4620
TTTAAAAATT AATAACGTTT GGGCAAAGGA TTTAATACGA GTTGTGCAAT TGTTTGIAAA	4680
GTCTAAT/CT TCTAAATCCT AATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT	4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTGTC	4800



AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	4860
TTTTTGATTT GCTGCTGGCT CTCAGCGTGG CACTGTTGCA GCGGGTGTTA ATACTGACCG	4920
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTTCGGT ATTTTAAATG GCGATGTTTT	4980
AGGGCTATCA GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG	5040
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTTTAT	5100
TACTGTCGT GTGACTGGTG AATCTGCCAA TGTAATAAAT CCATTTTACA CGATTGACCG	5160
TCAAAATGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTAATATTGT	5220
TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTTCCTCT ACTCAGGCAA GTGATGTTAT	5280
TACTAATCAA AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT	5340
CGGTGGCCTC ACTGATTATA AAAAGACTTC TCAAGATTCT GCGGTACCGT TCCTGTCTAA	5400
AATCCCTTTA ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAAGCACGTT	5460
ATACGTGCTC GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATT AAGCGGCGCG	5520
GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT	5580
TGCTTTTCTT CCCTTCCTTT CTGCGCACGT TCGCGGGCTT TCCCGTCAA GCTCTAAATC	5640
GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAACTTG	5700
ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA	5760
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA AACTCAACC	5820
CTATCTCGGG CTATTCTTTT GATTATAAG GGATTTTGCC GATTTTCGAA CCACCATCAA	5880
ACAGGATTTT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG	5940
CCAGGCGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCTT	6000
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC	6060
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC	6120
TCACTCATT A GGCACCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA	6180
TTGTGAGCGG ATAACAATTT CACACGCCAA GGAGACAGTC ATAATGAAAT ACCTATTGCC	6240
TACGGCAGCC GCTGGATTGT TATTACTCGC TGCCCAACCA GCCATGGCCG AGCTCGTGAT	6300
GACCCAGACT CCAGATATCC AACAGGAATG AGTGTTAATT CTAGAACCGC TCACTTGCCA	6360
CTGGCCGTGG TTTTACAACG TCGTGAATGG GAAAACCCTG GCGTTACCCA AGCTTAATCG	6420
CCTTGAGAAA TTCCCTTTTCG CCAGCTGGCG TAATAGCGAA GAGGCCCGCA CCGATCGCCC	6480
TTCCCAACAG TTGGGCAGCC TGAATGGCGA ATGGCGCTTT GCCTGGTTTC CGGCACCAGA	6540
AGCGGTGCGG GAAAGCTGGC TGGAGTGCGA TCTTCCTGAG GCCGATACGG TCGTCGTCCC	6600
CTCAAACCTG GAGATGCACG GTTACGATGC GCCGATCTAC ACCAACGTAA CCTATCCCAT	6660
TACGGTCAAT CCGCCGTTTG TTCCGACGGA GAATCCGACG GGTGTTTACT CGCTCACATT	6720
TAATGTTGAT GAAAGCTGGC TACAGGAAGG CCAGACGCGA ATTATTTTTC ATGGCGTTCC	6780
TATTGGTTAA AAAATGAGCT GATTAAACAA AAATTTAACG CGAATTTTAA CAAAATATTA	6840

50

ACGTTTACAA TTAAATATT TGCTTATACA ATCTTCCTGT TTTTGGGGCT TTTCTGATT	6900
TCAACCGGGG TACATATGAT TGACATGCTA GTTTTACGAT TACCGTTCAT CGATTCTCTT	6960
GTTTGCTCCA GACTCTCAGG CAATGACCTG ATAGCCTTTG TAGATCTCTC AAAAATAGCT	7020
ACCCTCTCCG GCATTAATTT ATCAGCTAGA ACGGTTGAAT ATCATATTGA TGGTGATTG	7080
ACTGTCTCCG GCCTTTCTCA CCCTTTTGAA TCTTTACCTA CACATTACTC AGGCATTGCA	7140
TTTAAATAT ATGAGGGTTC TAAAAATTTT TATCCTTGCG TTGAAATAAA GGCTTCTCCC	7200
GCAAAAGTAT TACAGGGTCA TAATGTTTTT GGTACAACCG ATTTAGCTTT ATGCTCTGAG	7260
GCTTIATTGC TTAATTTTGC TAATCTTTG CCTTGCTGT ATGATTATT GGATGTT	7317

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7729 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: circular

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTGCGGCCCC AAATGAAAAT	60
ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC AACTGTTACA TGAATGAAA CTTCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA	240
TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTTG CTTCGGTCT GGTTCGCTTT GAAGCTCGAA TTAACCGCG ATATTTGAAG	360
TCTTCGGGC TTCCTCTTAA TCTTTTGTAT GCAATCCGCT TTGCTTCTGA CTATAATAGT	420
CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTTA CTATTACCCC CTCTGGCAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT	600
GGTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	660
AATTCCTTTT GCGGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCGAATT TACTACTCGT TCTGGTGTTT	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTGT TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGCAAG ATTACTCTTG ATGAAGTCA GCCAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCGCGCCT CGTTCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCTA CACAATTTAT	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTCGGCGC TTGGTATAAT CGCTGGGGGT	1200

CAAAGATGAG TGTTTTAGTG TATTCCTTCG CCTCTTCGT TTTAGGTTGG TGCCTTCGTA	1260
GTGGCATTAC GTATTTTACC CGTTTAATGG AAACCTCCTC ATGAAAAAGT CTTTAGTCCT	1320
CAAAGCCTCT GTAGCCGTTG CTACCCCTCGT TCCCTTGCTG TCTTTCGCTG CTGAGGGTGA	1380
CGATCCGCA AAAGCGGCCT TTAACCTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTGA	1440
TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTTAAGAA	1500
ATTACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1560
TTTTTGAGA TTTCAACGT GAAAAATTA TTATCGCAA TTCCTTAGT TGTTCCCTTC	1620
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCGATAC AGAAAATTCA	1680
TTTACTAACG TCTGGAAAGA CGACAAACT TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1740
CTGTGGAATG CTACAGGCGT TGTAAGTTGT ACTGGTGACG AAATCAGTG TTACGGTACA	1800
TGGGTTCTTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TCTGAGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1920
ATTCCGGGCT ATACTTATAT CAACCCCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1980
AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT	2040
CAGAATAATA GGTTCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2100
CAAGGCACTG ACCCCGTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTGG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GCTGGGGGCG GCTCTGGTGG TGTTCTGGT GCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GCGGTTCCG GTGGTGGCTC TGTTCCGGT	2400
GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGG CTATGACCGA AAATGCCGAT	2460
GAAAACGCGC TACAGTCTGA CGCTAAAGGC AAACCTGATT CTGTCGCTAC TGATTACGGT	2520
GCTGCTATCG ATGGTTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2700
TTTGTCTTTA GGGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2760
TTCCGTGGTG TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG	2820
TTTGCTAACA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCGGT	2880
TATTATTGCG TTTCCTCGGT TTCCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTGGGTAAG ATAGCTATTG CTATTTCAAT GTTTCCTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTG TGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3060
TTGTTCAAGG TGTTCACTTA ATTCTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTC	3120
TCTCTGTAAA GGCTGCTATT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG	3180
ATTGGGATAA ATAATATGGC TGTTATTTTT GTAAGTGGCA AATTAGGCTC TGAAAGACG	3240

CTCGTTAGCG TTGGTAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	3300
CTTGATTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT	3360
CTTAGAATAC CGGATAAGCC TTCTATATCT GATTTGCTTG CTATTGGGCG CGGTAATGAT	3420
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGC GGTTAC TTGGTTTAAT	3480
ACCGGTCTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCGT	3540
AAATTAGGAT GGGATATTAT TTTTCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG	3600
CGTTCTGCAT TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	3660
TTTGTCGGTA CTTTATATTC TCTTATTACT GGCTCGAAAA TGCCTCTGCC TAAATTACAT	3720
GTTGGCGTTG TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT	3780
ACTGGTAAGA ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTTCTAG TAATTATGAT	3840
TCCGGTGTTT ATTCTTATTT AACGCCCTAT TTATCAGACG GTCGGTATTT CAAACCATTA	3900
AATTTAGGTC AGAAGATGAA GCTTACTAAA ATATATTTGA AAAAGTTTTC ACGCGTTCTT	3960
TGTCTTGCGA TTGGATTGTC ATCAGCATT ACATATAGTT ATATAACCCA ACCTAAGCCG	4020
GAGGTAAAA AGGTAGTCTC TCAGACCTAT GATTTTGATA AATTCACTAT TGA CTCTTCT	4080
CAGCGTGTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	4140
AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TACTGTTTCC	4200
ATTAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGTTT TCTTGATGTT	4260
TGTTTCATCA TCTTCTTTTG CTCAGGTAAT TGAAATGAAT AATTCGCCTC TGCGCGATT	4320
TGTAACCTGG TATTCAAAGC AATCAGGCGA ATCCGTTATT GTTCTCTCCG ATGTAAAGG	4380
TACTGTTACT GTATATTCAT CTGACGTAA ACCTGAAAA CTACGCAATT TCTTTATTT	4440
TGTTTTACGT GCTAATAATT TTGATATGGT TGTTTCAATT CCTTCGATAA TTCAGAAGTA	4500
TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	4560
TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TTA CTCAAAC	4620
TTTTAAAATT AATAACGTT C GGGCAAAGGA TTTAATACGA GTTGTGGAAT TGTTTGTA	4680
GTCTAATACT TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT	4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTTGCC	4800
AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	4860
TTTTTCATTT GCTGCTGGCT CTCAGCGTGG CACTGTTGCA GGCGGTGTTA ATACTGACCG	4920
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTCCGT ATTTTAAATG GCGATGTTTT	4980
AGGGCTATCA GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG	5040
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTTTAT	5100
TACTGGTCGT GTGACTGGTG AATCTGCCAA TGTAATAAAT CCATTTCAGA CGATTGAGCG	5160
TCAAAA TGTGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTAATATTGT	5220
TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTCTTCT ACTCAGGCAA GTGATGTTAT	5280

TACTAATCAA AGAAGTATTG CTACAACGGT TAATTGCGT GATGGACAGA CTCTTTTACT	5340
CGGTGGCCTC ACTGATTATA AAAACACTTC TCAAGATTCT GCGGTACCGT TCCTGTCTAA	5400
AATCCCTTTA ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAAGCACGTT	5460
ATACGTGCTC GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATT ACGCGGGCGG	5520
GTGTGCTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT	5580
TCGCTTCTT CCCTTCCTTT CTCGCCACGT TCGCGGGCTT TCCCGTCAA GCTCTAAATC	5640
GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAACTTG	5700
ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT GCGCCTTTGA,	5760
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACACTCAACC	5820
CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTTCGGAA CCACCATCAA	5880
ACAGGATTTT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG	5940
CCAGCGGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCCT	6000
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC	6060
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGACGCAA CGCAATTAAT GTGAGTTAGC	6120
TCACTCATT A GGCACCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGAA	6180
TTGTGAGCGG ATAACAATTT CACACGCGTC ACTTGCCACT GGCCGTCGTT TTACAACGTC	6240
GTGACTGGGA AAACCCTGGC GTTACCCAAG CTTTGTACAT GGAGAAAATA AAGTGAAACA	6300
AAGCACTATT GCACTGGCAC TCTTACCGTT ACTGTTTACC CCTGTGGCAA AAGCCCAGGT	6360
CCAGCTGCTC GAGTCGGTCT TCCCCCTGGC ACCCTCCTCC AAGAGCACCT CTGGGGGCAC	6420
AGCGGCCCTG GGCTGCCTGG TCAAGACTAA TTCCCCGAAC CGGTGACGGT GTCGTGGAAC	6480
TCAGGCGCCC TGACCAGCGG CGTGCACACC TTCCCGGCTG TCCTACAGTC CTCAGGACTC	6540
TACTCCCTCA GCAGCGTGGT GACCGTGCCC TCCAGCAGCT TGGGCACCCA GACCTACATC	6600
TGCAACGTGA ATCACAAGCC CAGCAACACC AAGGTGGACA AGAAAGCAGA GCCCAAATCT	6660
TGTACTAGTG GATCCTACCC GTACGACGTT CC ACTACG CTTCTTAGGC TGAAGGCGAT	6720
GACCTGCTA AGGCTGCATT CAATAGTTTA CAGJCAAGTG CTA CTGAGTA CATTGGCTAC	6780
GCTTGGGCTA TGGTAGTACT TATAGTTGGT GCTACCATAG GGATTAAATT ATTCAAAAAG	6840
TTTACGAGCA AGGCTTCTTA AGCAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC	6900
AGTTGCGCAG CCTGAATGGC GAATGGCGCT TTGCCTGGTT TCCGGCACCA GAAGCGGTGC	6960
CGGAAAGCTG GCTGGAGTGC GATCTTCCTG AGGCCGATAC GGTGCTCGTC CCCTCAAAC	7020
GGCAGATGCA CGGTTACGAT GCGCCGATCT ACACCAACGT AACCTATCCC ATTACGGTCA	7080
ATCCGCGGTT TGTTCCACAG GAGAATCCGA CGGGTTGTTA CTCGCTCAGA TTAAATGTTG	7140
ATGAAAGCTG GCTACAGGAA GGCCAGACGC GAATTATTTT TGATGGCGTT CCTATTGGTT	7200
AAAAATGAG CTGATTTAAC AAAAAATTAA CGCGAATTTT AACAAAATAT TAACGTTTAC	7260
AATTTAAATA TTTGCTTATA CAATCTTCCT GTTTTTGGGG CTTTTCTGAT TATCAACCGG	7320

GGTACATATG ATTGACATGC TAGTTTTACG ATTACCGTTC ATCGATTCTC TTGTTTGCTC	7380
CAGACTCTCA GGCAATGACC TGATAGCCTT TGTAGATCTC TCAAAAATAG CTACCCTCTC	7440
CGGCATTAAT TTATCAGCTA GAACGGTTGA ATATCATATT GATGGTGATT TGA CTGCTC	7500
CGGCCTTTCT CACCCTTTTG AATCTTTACC TACACATTAC TCAGGCATTG CATTTAAAAAT	7560
ATATGAGGGT TCTAAAAATT TTTATCCTTG CGTTGAAATA AAGGCTTCTC CCGCAAAAGT	7620
ATTACAGGGT CATAATGTTT TTGGTACAAC CGATTTAGCT TTATGCTCTG AGGCTTTTATT	7680
GCTTAATTTT GCTAATTCTT TGCCTTGCCT GTATGATTTA TTGGACGTT	7729

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 7557 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: both
  - (D) TOPOLOGY: circular

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAAT	60
ATAGCTAAAC AGGTTATTGA CCATTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTGCGAGA ATTGGGAATC AACTGTTACA TGGAAATGAAA CTTCAGACA CCGTACTTTA	180
GTTGCATATT TAAAAATGT TGAGCTACAG CACGAGATTC AGCAATTAAG CTCTAAGCCA	240
TCCGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTTG CTTCGGGTCT GGTTCGCTTT GAAGCTCGAA TTAACGCG ATATTGAAG	360
TCTTCGGGC TTCCTCTTAA TCTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAAGT	420
CAGGGTAAAG ACCTGATTTT TGATTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTTA CTATTACCCC CTCTGGCAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT	600
GGTTTTTATC TCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	660
AATTCCTTTT GCGGTTATGT ATCTGCATTA GTTGAATGTG GTATTCTTAA ATCTCAACTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTAGTTC GTTTTATTAA CGTAGATTTT	780
TGTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTT	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCTG CGGATTTCGA CACAATTIAT	1140
TAGCGATGA TACAAATCTC CGTTGTAATT TGTTCGCGC TTGGTATAAT CGCTGGGGGT	1200
CAAAGATGAG TGTTTTAGTG TATCTTTTCG CCTCTTTCGT TTTAGGTTGG TGCCTTCGTA	1260

GTGGCATTAC GTATTTTACC CGTTTAAATGG AAACCTTCCTC ATGAAAAAGT CTTTAGTCCT	1320
CAAAGCCTCT GTAGCCGTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT TTAACCTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	1440
TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTTAAGAA	1500
ATTACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1560
TTTTTGAGA TTTTCAACGT GAAAAAATTA TTATTGCGAA TTCCTTTAGT TGTTCCCTTC	1620
TATTCTCACT CCGCTGAAAC TGTTGAAAAGT TGTTTACGAA AACCCCATAC AGAAAATTCA	1680
TTTACTAAG TCTGAAAAGA CGACAAAACCT TTAGATCGTT ACGCTAATA TGAGGGTTGT,	1740
CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACCTCAGT TTACGGTACA	1800
TGGGTTCTTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1920
ATTCCGGGCT AACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1980
AACCCCGCTA ATCCTAATCC TTCTCTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT	2040
CAGAATAATA GGTTCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTACT	2100
CAAGGCACTG ACCCCGTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCAATTCTGG CTTTAATGAA	2220
GATCCATTG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG TGTTCTGGT GCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GCGGTTCCG GTGGTGGCTC TGTTCCGGT	2400
GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGG CTATGACCGA AAATGCCGAT	2460
GAAAACGCGC TACAGTCTCA CGCTAAAGGC AAACCTTGATT CTGTCGCTAC TGATTACGGT	2520
GCTGCTATCG ATGGTTTICAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2700
TTTGTCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2760
TTCCGTGGTG TCTTTCGCTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG	2820
TTTGCTAACA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCCGT	2880
TATTATTGCG TTCTCTCGGT TTCCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CCTGTTCTT GCTCTTATTA TTGGGCTTAA	3000
CTCAATTCTT GTGGGTATC TCTCTGATAT TAGCGCTCAA TIACCCTCTG ACTTTGTTCA	3060
GGGTGTTTCA TTAATTCTCC CGTCTAATGC GCTTCCTGT TTTTATGTTA TTCTCTCTGT	3120
AAAGGCTGCT ATTTTCATTT TTGACGTAA ACAAAAAATC GTTTCTTATT TGGATTGGGA	3180
TAAATAATAT GGCTGTTTAT TTTGTAAGT GCAAAATTAG CTCTGAAAAG ACGCTCGTTA	3240
CGGTTGGTAA GATTCAGGAT AAAATTGTAG CTGGGTGCAA AATAGCAACT AATCTTGATT	3300

TAAGGCTTCA	AAACCTCCCG	CAAGTCGGGA	GGTTCGCTAA	AAGGCCTCGC	GTTCTTAGAA	3360
TACCGGATAA	GCCTTCTATA	TCTGATTGTC	TTGCTATTGG	GCGCGGTAAT	GATTCTACG	3420
ATGAAAATAA	AAACGGCTTG	CTTGTTCTCG	ATGAGTGCGG	TACTTGGTTT	AATACCCGTT	3480
CTTGGAATGA	TAAGGAAAGA	CAGCCGATTA	TTGATTGGTT	TCTACATGCT	CGTAAATTAG	3540
GATGGGATAT	TATTTTCTT	GTTCAGGACT	TATCTATTGT	TGATAAACAG	GCGCGTTCTG	3600
CATTAGCTGA	ACATGTTGTT	TATTGTCGTC	GTCTGCACAG	AATTACTTTA	CCTTTTGTCTG	3660
GTACTTTATA	TTCTCTTATT	ACTGGCTCGA	AAATGCCTCT	GCCTAAATTA	CATGTTGGCG	3720
TTGTTAAATA	TGGCGATTCT	CAATTAAGCC	CTACTGTTGA	GCGTTGGGTT	TATACTGGTA	3780
AGAATTTGTA	TAACGCATAT	GATACTAAAC	AGGCTTTTTC	TAGTAATTAT	GATTCCGGTG	3840
TTTATTCTTA	TTTAACGCCT	TATTTATCAC	ACGGTCGGTA	TTTCAAACGA	TTAAATTTAG	3900
GTGAGAAGAT	GAAGCTTACT	AAAATATATT	TGAAAAAGTT	TTCACGCGTT	CTTTGTCTTG	3960
CGATTGGATT	TGCATCAGCA	TTTACATATA	GTTATATAAC	CCAACCTAAG	CCGGAGGTTA	4020
AAAAGGTAGT	CTCTCAGACC	TATGATTTTG	ATAAATTCAC	TATTGACTCT	TCTCAGCGTC	4080
TTAATCTAAG	CTATCGCTAT	GTTTTCAAGG	ATTCTAAGGG	AAAATTAATT	AATAGCGACG	4140
ATTTACAGAA	GCAAGGTTAT	TCACTCACAT	ATATTGATTT	ATGTACTGTT	TCCATTAAAA	4200
AAGGTAATTC	AAATGAAATT	GTTAAATGTA	ATTAAATTTG	TTTTCTTGAT	GTTTGTTTCA	4260
TCATCTTCTT	TTGCTCAGGT	AATTGAAATG	AATAATTCGC	CTCTGCGCGA	TTTTGTAACT	4320
TGGTATTCAA	AGCAATCAGG	CGAATCCGTT	ATTGTTTCTC	CCGATGTAAA	AGGTACTGTT	4380
ACTGTATATT	CATCTGACGT	TAAACCTGAA	AATCTACGCA	ATTTCTTTAT	TTCTGTTTTA	4440
CGTGCTAATA	ATTTTGATAT	GGTTGGTTCA	ATTCCTTCCA	TAATTCAGAA	GTATAATCCA	4500
AACAATCAGG	ATTATATTGA	TGAATTGCCA	TCATCTGATA	ATCAGGAATA	TGATGATAAT	4560
TCCGCTCCTT	CTGGTGGTTT	CTTTGTTCGG	CAAAATGATA	ATGTTACTCA	AACTTTTAAA	4620
ATTAATAACG	TTCGGGCAAA	GGATTTAATA	CGAGTTGTCG	AATTGTTTGT	AAAGTCTAAT	4680
ACTTCTAAAT	CCTCAAATGT	ATTATCTATT	GACGGCTCTA	ATCTATTAGT	TGTTAGTGCA	4740
CCTAAAGATA	TTTLAGATAA	CCTTCCTCAA	TTCTTTCTA	CTGTTGATTT	GCCAACTGAC	4800
CAGATATTGA	TTGAGGGTTT	GATATTTGAG	GTTCAGCAAG	GTGATGCTTT	AGATTTTTCA	4860
TTTGCTGCTG	GCTCTCAGCG	TGGCACTGTT	GCAGGCGGTG	TTAATACTGA	CCGCCTGACC	4920
TCTGTTTTAT	CTTCTGCTGG	TGGTTCGTTT	GGTATTTTTA	ATGGCGATGT	TTTAGGGCTA	4980
TCAGTTCGCG	CATTAAAGAC	TAATAGCCAT	TCAAAAATAT	TGTCTGTGCC	ACGTATTCTT	5040
ACGCTTTTCAG	GTGAGAAGGG	TTCTATCTCT	GTTGGCCAGA	ATGTCCTTTT	TATTACTGGT	5100
CGTGTGACTG	GTGAATCTGC	CAATGTAAAT	AATCCATTTT	AGACGATTGA	GCGTCAAAAT	5160
GTAGGTATTT	CCATGAGCGT	TTTCCTGTT	GCAATGGCTG	GCGGTAATAT	TGTTCTGGAT	5220
ATTACCAACA	AGGCCGATAG	TTGAGTTCT	TCTACTCAGG	CAAGTGATGT	TATTACTAAT	5280
CAAAGAAGTA	TTGCTACAAC	GGTTAATTTG	CGTGATGGAC	AGACTCTTTT	ACTCGGTGGC	5340



CTCACTGATT ATAAAAACAC TTCTCAAGA <sup>-</sup> TCTGGCGTAC CGTTCCTGTC TAAAATCCCT	5400
TTAATCGGCC TCCTGTTTAG CTCCCGCTCT GATTCCAACG AGGAAAGCAC GTTATACGTG	5460
CTCGTCAAAG CAACCATAGT ACGCGCCCTG TAGCGGCGCA TTAAGCGCGG CGGGTGTGGT	5520
GGTTACGGCG AGCGTGACCG CTACACTGCG CAGCGCCCTA GCGCCCGCTC CTTTCGCTTT	5580
CTTCCCTTCC TTTCTCGCCA CGTTGGCGGG CTTTCCCCGT CAAGCTCTAA ATCGGGGGCT	5640
CCCTTTAGGG TTCCGATTGA GTGCTTTACG GCACCTCGAC CCCAAAAAAC TTGATTTGGG	5700
TGATGGTTCA CGTAGTGGGC CATCGCCCTG ATAGACGGTT TTTGCGCCTT TGACGTTGGA	5760
GTCCACGTTT TTTAATAGTG GACTCTTGTT CCAAAGTGA ACAACACTCA ACCCTATCTC	5820
GGGCTATTCT TTGATTTAT AAGGGATTTT GCCGATTTG GAACCACCAT CAAACAGGAT	5880
TTTCGCCTGC TGGGGCAAAC CAGCGTGGAC CGTTGCTGC AACTCTCTCA GGGCCAGGGC	5940
GTGAAGGGCA ATCAGCTGTT GCCCGTCTCG CTGCTGAAAA GAAAAACCAC CCTGGCGCCC	6000
AATACGCAAA CCGCCTCTCC CCGCGCGTTG GCCGATTCAT TAATGCAGCT GGCACGACAG	6060
GTTTCCCGAC TGGAAAGCGG GCAGTGAGCG CAACGCAATT AATGTGAGTT AGCTCA <sup>2</sup> A	6120
TTAGGCACCC CAGGCTTTAC ACTTTATGCT TCCGGCTCGT ATGTTGTGTG GAATTG <sup>2</sup> AG	6180
CGGATAACAA TTTCACACGC CAAGGAGACA GTCATAATGA AATACCTATT GCCTACGGCA	6240
GCCGCTGGAT TGTTATTACT CGCTGCCCAA CCAGCCATGG CCGAGCTCTT CCGGCCATCT	6300
GATGAGCAGT TGAAATCTGG AACTGCCTCT GTTGTGTGCC TGCTGAATAA CTTCTATCCC	6360
AGAGAGGCCA AAGTACAGTG GAAGGTGGAT AACGCCCTCC AATCGGGTAA CTCCAGGAG	6420
AGTGTCACAG AGCAGGACAG CAAGGACAGC ACCTACAGCC TCAGCAGCAC CCTGACGCTG	6480
AGCAAAGCAG ACTACGAGAA ACACAAAGTC TACGCCTGCG AAGTCACCCA TCAGGGCCTG	6540
AGCTCGCCCG TCACAAAGAG CTTCAACAGG GGAGAGTGTT CTAGAACGCG TCACTTGGCA	6600
CTGGCCGTG TTTTACAACG TCGTGACTGG GAAAACCCTC GCGTTACCCA AGCTTAATCG	6660
CCTTGCAGAA TTCCCTTTG CCAGCTGGCG TAATAGCGAA GAGGCCCGCA CCGATCGCCC	6720
TTCCCAACAG TTGCGCAGCC TGAATGCCGA ATGGCGCTTT GCCTGGTTTC CGGCACCAGA	6780
AGCGGTGCCG GAAAGCTGGC TGGAGTGCGA TCTTCCTGAG GCCGATACGG TCGTCGTCCC	6840
CTCAAACTGG CAGATGCAGG GTTACGATGC GCCCATCTAC ACCAACGTAA CCTATCCCAT	6900
TACGGTCAAT CCGCGGTTTG TTCCACGGA GAATCCGACG GGTGTGTTACT CGCTCACATT	6960
TAATGTTGAT GAAAGCTGGC TACAGGAAGG CCAGACGCGA ATTATTTTTG ATGGCGTTCC	7020
TATTGGTTAA AAAATGAGCT GATTTAACAA AAATTTAACG CGAATTTTAA CAAAATATTA	7080
ACGTTTACAA TTTAAATATT TGCTTATACA ATCTTCCTGT TTTGGGGCT TTTCTGATTA	7140
TCAACCGGGG TACATATGAT TGACATGCTA GTTTTACGAT TACCGTTCAT CGATTCTCTT	7200
GTTTGCTCCA GACTCTCAGG CAATGACCTG ATAGCCTTTG TAGATCTCTC AAAAATAGCT	7260
ACCCTCTCCG GCATTAAATTT ATCAGCTAGA ACGGTTGAAT ATCATATTGA TGGTGATTTG	7320
ACTGTCTCCG GCCTTTCTCA CCCTTTTGAA TCTTTACCTA CACATTACTC AGGCATTGCA	7380

TTTAAATAT ATGAGGGTTC TAAAAATTTT TATCCTTGCG TTGAAATAAA GGCTTCTCCC 7440  
 GCAAAAGTAT TACAGGGTCA TAATGTTTTT GGTACAACCG ATTTAGCTTT ATGCTCTGAG 7500  
 GCTTTATTGC TTAATTTTGC TAATTCCTTG CCTTGCCTGT ATGATTTATT GGATGTT 7557

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8118 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: circular

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTGAG CTCGCGCCCC AAATGAAAAT 60  
 ATAGCTAAAC AGGTIATTGA CCATTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT 120  
 CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA 180  
 GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA 240  
 TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG 300  
 TTGGAGTTTG CTTCGGGTCT GGTTCGCTTT GAAGCTCGAA TAAAACGCG ATATTTGAAG 360  
 TCTTTCGGGC TTCCTCTTAA TCTTTTIGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT 420  
 GAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA 480  
 TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT 540  
 AAACATTTTA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT 600  
 GGTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT 660  
 AATTCCTTTT GCGGTIATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG 720  
 ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT 780  
 TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA 840  
 CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTC 900  
 CTCGTACAGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG 960  
 AATATCCGGT TCTTGCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC 1020  
 TGACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCTT ATGATTGACC 1080  
 GTCTGCGCCT CGTTCGGCT AAGTAACATG GAGCAGGTG CGGATTCGA CACAATTTAT 1140  
 CAGGCGATGA TAGAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT 1200  
 CAAAGATGAG TGTTTATAGT TATTCCTTCG CCTCTTTCGT TTTAGGTTGG TGCCTTCGTA 1260  
 GTGGCATTAC GTATTTTACC CGTTTAATGG AAACCTCCTC ATGAAAAAGT CTTTAGTCCT 1320  
 CAAAGCCTCT GTAGCCGTTG CTACCCCTGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA 1380  
 CATCCCGCA AAAGCGGCCT TTAACCTCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA 1440  
 TCGCTGGGCG ATGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTTAAGAA 1500

ATTACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1560
TTTTTGGAGA TTTTCAACGT GAAAAAATTA TTATTGCGAA TTCCTTTAGT TGTTCCTTTC	1620
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AGAAAATTCA	1680
TTTACTAACG TCTGGAAAGA CGACAAAAC TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1740
CTGTGGAATG CTACAGGCGT TGTAAGTTGT ACTGGTGACG AAATCAGTG TTACGGTACA	1800
TGGGTTCTTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1920
ATTCGGGGCT ATACTTATAT CAACCCCTCTC GACGGCATT ATCCGCCTGG TACTGAGCAA	1980
AACCCCGCTA ATCCTAATCC TTCTCTTGA GAGTCTCAGC CTCTTAATAC TTTTATGTTT	2040
CAGAATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2100
CAAGGCACTG ACCCCGTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTCTG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG TGTTCTGGT GCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GCGGTTCCG GTGGTGGCTC TGTTCCGGT	2400
GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGG CTATGACCGA AAATGCCGAT	2460
GAAAACGCGC TACAGTCTGA CGCTAAAGGC AAATTTGATT CTGTCGCTAC TGATTACGGT	2520
GCTGCTATCG ATGGTTTQAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGGCCT	2700
TTTGCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2760
TTCCGTGGTG TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTCTACG	2820
TTTGCTAACA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCCGT	2880
TATTATTGCG TTTCCTCGGT TTCCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CTATTTTATT GTTTCTTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTGTG GGTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3060
TTGTTTCAAGG TGTTTCACTA ATTCTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTG	3120
TCTCTGTAAA GGCTGCTATT TTGATTTTGT ACCTTAAACA AAAATCGTT TCTTATTTGG	3180
ATTGGGATAA ATAATATGGC TGTATTATTT GTAACGGCA AATTAGGCTC TGGAAAGACG	3240
CTCGTTAGCG TTGGTAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	3300
CTTGATTTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAC GCCTCGCGTT	3360
CTTAGAATAC CGGATAAGCC TTCTATATCT GATTTGCTTG CTATTGGGCG CGGTAATGAT	3420
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGGGTAC TTGGTTTAAT	3480
ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCGT	3540

AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTGGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTGGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AAGGCCTTAT	TTATCAGACG	GTCGGTATTT	CAAACCATT	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTGTA	AAAAGTTTTC	ACGCGTTCTT	3960
TGCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTATTCA	CTCACATATA	TTGATTIATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACCTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAGG	4380
TACTGTIACT	GTATATTCAT	CTGACGTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTT	4440
TGTTTTAGCT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAAAT	AATAACGTTT	GGGCAAAGGA	TTAATACGA	GTTGTGGAAT	TGTTTGTAAT	4680
GTCTAATACT	TCTAAATCCT	GAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTCTACTG	TTGATTTGCC	4800
AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACGTGTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCCGT	ATTTTAAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTGCGGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTTACA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCCTC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATT	AGCGCGGGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACCTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580

TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCGTCAA GCTCTAAATC 5640  
GGGGGCTCCC TTTAGGGTTC CGATTIAGTG CTTTACGGCA CCTCGACCCC AAAAAACTTG 5700  
ATTTGGGTGA TGGTTCACGT AGTGGGGCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA 5760  
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCTA AACTGGAACA AACTCAACC 5820  
CTATCTCGG CTATTCCTTT GATTTATAAG GGATTTTGCC GATTTGCGAA CCACCATCAA 5880  
ACAGGATTTT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG 5940  
CCAGGCGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCCT 6000  
GGCGCCCAAT ACGCAAACCG CCTCTCCCGG CGCGTTGGCC GATTCATTAA TGCAGCTGGC 6060  
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC 6120  
TCACTCATTG GGCACCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA 6180  
TTGTGAGCGG ATAACAATTT CACACGCCAA GGAGACAGTC ATAATGAAAT ACCTATTGCC 6240  
TACGGCAGCC GCTGGATTGT TATTACTCGC TGCCCAACCA GCCATGGCCG AGCTCTTCCC 6300  
GCCATCTGAT GAGCAGTTGA AATCTGGAAC TGCCTCTGTT GTGTGCCTGC TGAATAACTT 6360  
CTATCCGAGA GAGGCCAAAG TACAGTGGAA GGTGGATAAC GCCCTCCAAT CGGGTAACTC 6420  
CCAGGAGACT GTCACAGAGC AGGACAGCAA GGACAGCACC TACAGCCTCA GCAGCACCTT 6480  
GACGCTGAGC AAAGCAGACT ACGAGAAACA CAAAGTCTAC GCCTGCGAAG TCACCCATCA 6540  
GGGCCTGAGC TCGCCCGTCA CAAAGAGCTT CAACAGGGGA GAGTGTCTA GAACGCGTCA 6600  
CTTGGCACTG GCCGTCGTTT TACAACGTCG TGAAGTGGAA AACCTGGCG TTACCCAAGC 6660  
TTTGTACATG GAGAAAATAA AGTGAAACAA AGCACTATTG CACTGGCACT CTTACCGTTA 6720  
CTGTTTACCC CTGTGGCAA AGCCGCTCC ACCAAGGGCC CATCGGTCTT CCCCTGGCA 6780  
CCCTCCTCCA AGAGCACCTC TGGGGGCACA GCGGCCCTGG GCTGCCTGGT CAAGACTAAT 6840  
TCCCGGAACC GGTGACGGTG TCGTGGAACT CAGGCGCCCT GACCAGCGGC GTGCACACCT 6900  
TCCCGGCTGT CCTACAGTCC TCAGACTCT ACTCCCTCAG CAGCGTGGTG ACCGTGCCCT 6960  
CCAGCAGCTT GGCACCCAG ACCTACATCT GCAACGTGAA TCACAAGCCC AGCAACACCA 7020  
AGGTGGACAA GAAAGCAGAG CCCAAATCTT GTACTAGTGG ATCCTACCCG TACGACGTT 7080  
CGGACTACGC TTCTTAGGCT GAAGGCGATG ACCCTGCTAA GGCTGCATTC AATAGTTTAC 7140  
AGGCAAGTGC TACTGAGTAC ATTGGCTACG CTTGGGCTAT GGTAGTAGTT ATAGTTGGTG 7200  
CTACCATAGG GATTAAATTA TTCAAAAAGT TTACGAGCAA GGCTTCTTAA GCAATAGCGA 7260  
AGAGGCCCCG ACCGATCGCC CTTCCCAACA GTTGGCAGC CTGAATGGCG AATGGCGCTT 7320  
TGCCTGGTTT CCGGCACCAG AAGCGGTGCC GGAAAGCTGG CTGGAGTGG ATCTTCTGA 7380  
GGCCGATACG GTCGTCGTCC CCTCAAACCTG GCAGATGCAC GGTACGATG CGCCCATCTA 7440  
CACCAACGTA ACCTATCCCA TTACGGTCAA TCGCCGTTT GTTCCACGG AGAATCCGAC 7500  
GGGTGTTTAC TCGCTCAGAT TTAATGTGTA TGAAAGCTGG CTACAGGAAG GCCAGACGG 7560  
AATTATTTTT GATGGCGTTC CTATTGGTTA AAAATGAGC TGATTTAACA AAAATTTAAC 7620

62

```

GCGAATTTTA ACAAATATT AACGTTTACA ATTTAAATAT TTGCTTATAC AATCTTCCTG      7680
TTTTTGGGGC TTTTCTGATT ATCAACCGGG GTACATATGA TTGACATGCT AGTTTACGA      7740
TTACCGTTCA TCGATTCTCT TGTTTGCTCC AGACTCTCAG-GCAATGACCT GATAGCCTTT      7800
GTAGATCTCT CAAAAATAGC TACCCTCTCC GGCATTAATT TATCAGCTAG AACGGTTGAA      7860
TATCATATTG ATGGTGATT GACTGTCTCC GGCCTTTCTC ACCCTTTTGA ATCTTTACCT      7920
ACACATTACT CAGGCATTGC ATTTAAAATA TATGAGGGTT CTAAAAATTT TTATCCTTGC      7980
GTTGAAATAA AGGCTTCTCC CGCAAAAGTA TTACAGGGTC ATAATGTTTT TGGTACAAGC      8040
GATTAGCTT TATGCTCTGA GGCTTTATTG CTAAATTTTG CTAATTCTTT GCCTTGCCCTG      8100
TATGATTIAT TGGACGTT                                                    8118

```

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ix) FEATURE:

- (A) NAME/KEY: misc difference
- (B) LOCATION: replace(5, "")
- (D) OTHER INFORMATION: /note= "S REPRESENTS EQUAL MIXTURE OF G AND C"

## (ix) FEATURE:

- (A) NAME/KEY: misc difference
- (B) LOCATION: replace(6, "")
- (D) OTHER INFORMATION: /note= "M REPRESENTS EQUAL MIXTURE OF A AND C"

## (ix) FEATURE:

- (A) NAME/KEY: misc difference
- (B) LOCATION: replace(8, "")
- (D) OTHER INFORMATION: /note= "R REPRESENTS EQUAL MIXTURE OF A AND G"

## (ix) FEATURE:

- (A) NAME/KEY: misc difference
- (B) LOCATION: replace(11, "")
- (D) OTHER INFORMATION: /note= "K REPRESENTS EQUAL MIXTURE OF G AND T"

## (ix) FEATURE:

- (A) NAME/KEY: misc difference
- (B) LOCATION: replace(20, "")
- (D) OTHER INFORMATION: /note= "W REPRESENTS EQUAL MIXTURE OF A AND T"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGGTSMARCT KCTCGAGTCW GG

22

63

## (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AGGTCCAGCT GCTCGAGTCT GG

22

## (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AGGTCCAGCT GCTCGAGTCA GG

22

## (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AGGTCCAGCT TCTCGAGTCT GG

22

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AGGTCCAGCT TCTCGAGTCA GG

22

## (2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

64

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AGGTCCAAC TCTCGAGTCT GG

22

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AGGTCCAAC TCTCGAGTCA GG

22

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AGGTCCAAC TCTCGAGTCT GG

22

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGGTCCAAC TCTCGAGTCA GG

22

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc\_difference
- (B) LOCATION: replace(5..6, "")
- (D) OTHER INFORMATION: /note= "N-INOSINE"

(ix) FEATURE:

- (A) NAME/KEY: misc\_difference
- (B) LOCATION: replace(8, "")
- (D) OTHER INFORMATION: /note= "N-INOSINE"



65

## (ix) FEATURE:

- (A) NAME/KEY: misc difference
- (B) LOCATION: replace(11, "")
- (D) OTHER INFORMATION: /note= "N-INOSINE"

## (ix) FEATURE:

- (A) NAME/KEY: misc difference
- (B) LOCATION: replace(20, "")
- (D) OTHER INFORMATION: /note= "W REPRESENTS EQUAL MIXTURE OF A AND T"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

AGGTNNANCT NCTCGAGTCW GG

22

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CTATTA ACTA GTAACGGTAA CAGTGGTGCC TTGCCCCA

38

## (2) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

AGGCTTACTA GTACAATCCC TGGGCACAAT

30

## (2) INFORMATION FOR SEQ ID NO:18:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCAGTTCCGA GTCGTTGTG ACTCAGGAAT CT

32

## (2) INFORMATION FOR SEQ ID NO:19:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

66

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CCAGTTCCGA GCTCGTGTTG ACGCAGCCGC CC

32

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCAGTTCCGA GCTCGTGCTC ACCCAGTCTC CA

32

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CCAGTTCCGA GCTCCAGATG ACCCAGTCTC CA

32

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CCAGATGTGA GCTCGTGATG ACCCAGACTC CA

32

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CCAGATGTGA GCTCGTCATG ACCCAGTCTC CA

32

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CCAGTTCCGA GCTCGTGATG ACACAGTCTC CA

32

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GCAGCATTCT AGAGTTTCAG CTCCAGCTTG CC

32

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 34 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GCGCCGTCTA GAATTACAC TCATTCTGT TGAA

34

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 37 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GATCCTAGGC TGAAGGCGAT GACCCTGCTA AGGCTGC

37

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 35 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

ATTCAATAGT TTACAGGCAA GTGCTACTGA GTACA

35

68

## (2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 35 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TTGGCTACGC TTGGGCTATG GTAGTAGTTA TAGTT

35

## (2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 35 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GGTGCTACCA TAGGGATTAA ATTATTCAAA AAGTT

35

## (2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

TACGAGCAAG GCTTCTTA

18

## (2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 39 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

AGCTTAAGAA GCCTTGCTCG TAAACTTTTT GAATAATTT

39

## (2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 36 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

69

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

AATCCCTATG GTAGCACCAA CTATAACTAC TAGCAT

36

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 35 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

AGCCCAAGCG TAGCCAATGT ACTCAGTAGC ACTTG

35

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 34 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

CCTGTAAACT ATTGAATGCA GCCTTAGCAG GGTC

34

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

ATCGCCTTCA GCCTAG

16

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CATTTTTGCA GATGGCTTAG A

21

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TAGCATTAAAG GTCCAATA

18

(2) INFORMATION FOR SEQ ID NO:39:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

ATATATTTTA GTAAGCTTCA TCTTCT

26

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GACAAAGAAC GCGTGAAAAC TTT

23

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 35 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

GCGGGCCTCT TCGCTATTGC TTAAGAAGCC TTGCT

35

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 43 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

AAACGACGGC CAGTGCCAAG TGACGCGTGT GAAATTGTIA TCC

43

71

## (2) INFORMATION FOR SEQ ID NO:43:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GGCGAAAGGG AATTCTGCAA GGCGATTAAG CTTGGGTAAC GCC

43

## (2) INFORMATION FOR SEQ ID NO:44:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GGCGTTACCC AAGCTTTGTA CATGGAGAAA ATAAAG

36

## (2) INFORMATION FOR SEQ ID NO:45:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

TGAAACAAAG CACTATTGCA CTGGCACTCT TACCGTTACC GT

42

## (2) INFORMATION FOR SEQ ID NO:46:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TACTGTTTAC CCCTGTGACA AAAGCCGCCC AGGTCCAGCT GC

42

## (2) INFORMATION FOR SEQ ID NO:47:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

72

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

TCGAGTCAGG CCTATTGTGC CCAGGGATTG TACTAGTGA TCCG

44

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

TGGCGAAAGG GAATTCGGAT CCACTAGTAC AATCCCTG

38

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GGCACAATAG GCCTGACTCG AGCAGCTGGA CCAGGGCGGC TT

42

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

TTGTCACAGG GGTAACAGT AACGGTAACG GTAAGTGTGC CA

42

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

GTGCAATAGT GCTTTGTTTC ACTTTATTTT CTCATGTAC AA

42

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

TAACGGTAAG AGTGCCAGTG C

21

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

CACCTTCATG AATTCGGCAA GGAGACAGTC AT

32

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

AATTCGCCAA GGAGACAGTC AT

22

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

AATGAAATAC CTATTGCCTA CGGCAGCCGC TGGATTGT

39

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

ATTACTCGCT GCCCAACCAG CCATGGCCGA GCTCGTGAT

39

## (2) INFORMATION FOR SEQ ID NO:57:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 39 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GACCCAGACT CCAGATATCC AACAGGAATG AGTGTTAAT

39

## (2) INFORMATION FOR SEQ ID NO:58:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

TCTAGAACGC GTC

13

## (2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 45 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

TTCAGGTTGA AGCTTACGCG TTCTAGAATT AACACTCATT CCTGT

45

## (2) INFORMATION FOR SEQ ID NO:60:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 39 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

TGGATATCTG GAGTCTGGGT CATCAGGAGC TCGGCCATG

39

## (2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 39 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

75

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

GCTGGTTGGG CAGCGAGTAA TAACAATCCA GCGGCTGCC

39

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

GTAGGCAATA GGTATTTTCAT TATGACTGTC CTTGGCG

37

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

TGACTGTCTC CTTGGCGTGT GAAATTGTTA

30

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

TAACACTCAT TCCGGATGGA ATTCTGGAGT CTGGGT

36

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

GCCAGTGCCA AGTGACGGT TCTA

24

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

ATATATTTTA GTAAGCTTCA TCTTCT

26

## (2) INFORMATION FOR SEQ ID NO:67:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

GACAAAGAAC GCGTGAAAAC TTT

23

## (2) INFORMATION FOR SEQ ID NO:68:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 76 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

CTGAACCTGT CTGGGACCAC AGTTGATGCT ATAGGATCAG ATCTAGAATT CATTAGAGA  
CTGGCCTGGC TTCTGC

60

76

## (2) INFORMATION FOR SEQ ID NO:69:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 80 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

TCGACCGTTG GTAGGAATAA TGCAATTAAT GGAGTAGCTC TAAATTCAGA ATTCATCTAC  
ACCCAGTGCA TCCAGTAGCT

60

80

## (2) INFORMATION FOR SEQ ID NO:70:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

GGTAAACATT AACGGTAAGA CCGCCAG

27

77

## (2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 54 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

CGCCTTCAGC CTAAGAAGCG TAGTCCGGAA CGTCGTACGG GTAGGATCCA CTAG

54

## (2) INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 41 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

CACCGGTTTCG GCGAATTAGT CTTGACCAGG CAGCCCAGGG C

41

## (2) INFORMATION FOR SEQ ID NO:73:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 51 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

ATTCCACACA TTATACGAGC CGGAAGCATA AAGTGTCAAG CCTGGGGTGC C

51

## (2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 42 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

CTGCTCATCA GATGGCGGGA AGAGCTCGGC CATGGCTGCT TG

42

## (2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 42 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

78

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:75:

GAACAGAGTG ACCGAGGGGG CGAGCTCGGC CATGGCTGGT TG

42

## I Claim:

1. A composition of matter comprising a plurality of cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form heteromeric receptors, one or both of said polypeptides being expressed as fusion proteins on the surface of a cell.
2. The composition of claim 1, wherein said plurality of cells are E. coli.
3. The composition of claim 1, wherein said heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
4. The composition of claim 1, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
5. The composition of claim 4, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
6. The composition of claim 1, wherein said cell produces filamentous bacteriophage.
7. The composition of claim 6, wherein said filamentous bacteriophage are selected from the group consisting of M13, fd and fl.
8. The composition of claim 6, wherein at least one of the encoded first or second polypeptides is expressed as a fusion protein with gene VIII.

9. A kit for the preparation of vectors useful for the coexpression of two or more DNA sequences encoding polypeptides which form heteromeric receptors comprising two vectors, a first vector having two pairs of restriction sites symmetrically oriented about a cloning site which can be combined with a second vector, having two pairs of restriction sites symmetrically oriented about a cloning site and in an identical orientation to that of the first vector, wherein one or both vectors contains sequences necessary for expression of polypeptides encoded by DNA sequences inserted in said cloning sites.

10. The kit of claim 9, wherein said first and second vectors are circular.

11. The kit of claim 9, wherein said expression peptides is as fusion proteins on the surface of a cell.

12. The kit of claim 9, wherein said cell produces filamentous bacteriophage.

13. The kit of claim 9, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.

14. The kit of claim 13, wherein at least one of the DNA sequences is expressed as a fusion protein with gene VIII.

15. The kit of claim 9, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.



16. A cloning system for the coexpression of two or more DNA sequences encoding polypeptides which form a heteromeric receptor, comprising a set of first vectors having a diverse population of first DNA sequences and a  
5 set of second vectors having a diverse population second DNA sequences, said first and second vectors having two pairs of restriction sites symmetrically oriented about a cloning site for containing said first and second  
10 populations of DNA sequences so as to allow only the operational combination of vector sequences containing said first and second DNA sequences.

17. The cloning system of claim 16, wherein said first and second vectors are circular.

18. The cloning system of claim 16, wherein said heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.

19. The cloning system of claim 16, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.

20. The cloning system of claim 19, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.

21. The cloning system of claim 16, wherein said coexpression of two or more DNA sequences encoding polypeptides which form a heteromeric receptor is on the surface of cell.

22. The cloning system of claim 16, wherein said cell produces a filamentous bacteriophage.

23. The cloning system of claim 22 wherein said filamentous bacteriophage selected from the group consisting of M13, fd and fl.

24. The cloning system of claim 23, wherein at least one of the DNA sequences is expressed as a fusion protein with the protein product of gene VIII.

25. The cloning system of claim 16, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

26. A plurality of expression vectors containing a plurality of possible first and second DNA sequences encoding polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule,  
5 said DNA sequence encoding heteromeric receptors being operatively linked to genes encoding surface proteins of a cell.

27. The expression vectors of claim 26, wherein said expression vectors are circular.

28. The expression vectors of claim 23, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.

29. The expression vectors of claim 26, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.

30. The expression vectors of claim 29, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.

31. The expression vectors of claim 26, wherein said cells produce filamentous bacteriophage.

32. The expression vectors of claim 26, wherein said filamentous bacteriophage are selected from the group consisting of M13, fd and fl.

33. The expression vectors of claim 32, wherein at least one of the encoded first or second polypeptides is expressed as a fusion protein with gene VIII.

34. A method of constructing a diverse population of vectors capable of expressing a diverse population of heteromeric receptors, comprising:

- 5 (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;
- 10
- (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector; and
- 15
- 20 (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.

35. The method of claim 34, wherein said first and second vectors are circular.

36. The method of claim 34, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.

37. The method of claim 34, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.

38. The method of claim 34, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell.

39. The method of claim 37, wherein said cell produces a bacteriophage.

40. The method of claim 39, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.

41. The method of claim 34, wherein at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.

42. The method of claim 34, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

43. The method of claim 34, wherein said combining step further comprises:

- 5 (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
- 10 (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
- (C3) digesting the 3' ends of said restricted first and second vectors with an exonuclease; and
- 15 (C4) annealing said first and second vectors.

44. A method for selecting a heteromeric receptor exhibiting binding activity toward a preselected molecule from a population of diverse heteromeric receptors, comprising:

- 5 (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;  
10
- (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector;  
15  
20
- (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.  
25
- (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences; and  
30
- (e) determining the heteromeric receptors which bind to said preselected molecule.

45. The method of claim 44, wherein said first and second vectors are circular.

46. The method of claim 44, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.

47. The method of claim 44, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.

48. The method of claim 47, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.

49. The method of claim 44, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell.

50. The method of claim 49, wherein said cell produces a filamentous bacteriophage.

51. The method of claim 50, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.

52. The method of claim 51, wherein at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.

53. The method of claim 44, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

54. The method of claim 44, wherein said combining step further comprises:

- 5 (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
- 10 (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
- (C3) digesting the 3' ends of said restricted first and second vectors with an exonuclease; and
- 15 (C4) annealing said first and second vectors.



55. A method for determining the nucleic acid sequences encoding a heteromeric receptor exhibiting binding activity toward a preselected molecule from a diverse population of heteromeric receptors, comprising:

- 5 (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;
- 10
- 15 (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector;
- 20
- 25 (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.
- 30 (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences;

- 5 (e) determining the heteromeric receptors which bind to said preselected molecule;
- (f) isolating the nucleic acid sequences encoding said first and second polypeptides; and
- (g) sequencing said nucleic acid sequences.

56. The method of claim 55, wherein said first and second vectors are circular.

57. The method of claim 55, wherein said first heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.

58. The method of claim 55, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.

59. The method of claim 58, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.

60. The method of claim 55, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell filamentous bacteriophage selected from the group consisting of M13, fd and f1 and at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.

61. The method of claim 55, wherein said cell produces filamentous bacteriophage.

62. The method of claim 61, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.

63. The method of claim 62, wherein at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.

64. The method of claim 50, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

65. The method of claim 50, wherein said combining step further comprises:

- 5 (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
- 10 (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
- (C3) digesting the 3' ends of said restricted first and second vectors with an exonuclease; and
- 15 (C4) annealing said first and second vectors.

66. A vector comprising two copies of a gene encoding a filamentous bacteriophage coat protein, one copy of said gene capable of being operationally linked to a DNA sequence encoding a polypeptide of a heteromeric receptor  
5 wherein said DNA sequence can be expressed as a fusion protein on the surface of said filamentous bacteriophage or as a soluble polypeptide.

67. The vector of claim 66, wherein said two copies of said gene encode substantially the same amino acid sequence but have different nucleotide sequences.

68. The vector of claim 66, wherein said one copy of said gene is expressed on the surface of said filamentous bacteriophage.

69. The vector of claim 66, wherein said bacteriophage coat protein is M13 gene VIII.

70. The vector of claim 66, wherein said vector has substantially the same sequence as that shown in Figure 2 (SEQ ID NO: 1).

71. A vector comprising sequences necessary for the coexpression of two or more inserted DNA sequences encoding polypeptides which form heteromeric receptors and two copies of a gene encoding a filamentous bacteriophage  
5 coat protein, one copy of said gene capable of being operationally linked to one of said two or more inserted DNA sequences wherein said DNA sequence can be expressed as a fusion protein on the surface of said filamentous bacteriophage or as a soluble polypeptide.

72. The vector of claim 71, wherein said two copies of said gene encode substantially the same amino acid sequence but have different nucleotide sequences.


73. The vector of claim 71, wherein said one copy of said gene is expressed on the surface of said filamentous bacteriophage.

74. The vector of claim 71, wherein said bacteriophage coat protein is M13 gene VIII.

75. The vector of claim 71, wherein said vector has substantially the same sequence as that shown in Figure 6 (SEQ ID NO: 5).

1 / 11

FIG. 1



SUBSTITUTE SHEET

2 / 11

	1	10	20	30	40	50	60
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
61	ATAGCTAAAC	AGGTTATTGA	GCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT	120
121	CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
181	GTTCGATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTG	AGCAATTAAG	CTCTAAGCCA	240
241	TCTGCAAAAA	TGACCTCTTA	TCAAAAAGGAG	CAATTAAGG	TACTCTCTAA	TCCAGACCTG	300
301	TTGGAGTTTG	CTTCCGGTCT	GGTTTCGCTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	360
361	TCTTTCCGGC	TTCTCTTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCAATCTCGT	TTTCTGAAT	GTTTAAAGCA	480
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCGCGAG	TATTGGACGC	TATCCAGTCT	540
541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAAGCCTC	TCGCTATTTT	600
601	GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
661	AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720
721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATPTT	780
781	TCTTCCCAAC	GTCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAAATCA	840
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTC	900
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAAATG	960
961	AATATCCGGT	TCTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCAGGTGGTC	1020
1021	TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
1081	GTCTGCGCCT	CGTTCCGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTTCGA	CACAAATTTAT	1140
1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
1201	CAAAGATGAG	TGTTTTAGTG	TATTTCTTCG	CCTCTTTTCG	TTTAGGTTGG	TGCTTTCGTA	1260
1261	GTTGGATTAC	GTATTTTACC	CGTTTAAAGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCTT	1320
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
1381	CGATCCCGCA	AAAGCGGCCT	TAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
1441	TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAAGAA	1500
1501	ATTCACCTCG	AAAGCAAGCT	GATAAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCTTTT	1560
1561	TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCTTTTAGT	TGTTCTTTTC	1620
1621	TATTTCTACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAAATTCA	1680
1681	TTTACTAACG	TCTGGAAGAA	CGACAAAAT	TTAGATCGTT	ACGCTAATCT	TGAGGGTTGT	1740
1741	CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAAGT	TTACGGTACA	1800
1801	TGGGTTCCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
1861	TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
1921	ATTCGGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
1981	AACCCGCTA	ATCCTAATCC	TTCTCTTAGG	GAGTCTCAGC	CTCTTAATAC	TTTCATCTTT	2040
2041	CAGAAATAA	GGTTCCGAAA	TAGGCAGGGG	GACCTAACGT	TTTATACGGG	CACTGTTACT	2100
2101	CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
2161	TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
2221	GATCCATTCTG	TTTGTGAATA	TCAAGGCCAA	TCTGTGACC	TGCCCAACC	TCCTGTCAAT	2280
2281	GCTGGCGGGC	GCTCTGGTGG	TGGTTCTGGT	GCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
2341	GCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GCGGTTCCG	GTGGTGGCTC	TGGTCCGGT	2400
2401	GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
2461	GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
2521	GCTGTATTCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGTACT	2580
2581	GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
2641	TTAATGAATA	ATTTCGCTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
2701	TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
2761	TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	TGTGCCACCT	TTATGTATGT	ATTTCTACG	2820
2821	TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCGGT	2880
2881	TATTATTGCG	TTTCTCGGT	TTCTTCTGG	TAACCTTGT	CGGCTATCTG	CTTACTTTTC	2940
2941	TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCAAT	GTTTCTTGCT	CTTATTATTG	3000
3001	GGCTTAACTC	AATTCCTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
3061	TTGTTACGGG	TGTTACGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTT	TATGTTATT	3120
3121	TCTCTGTAAA	GGCTGCTATT	TTTATTTTGG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
3181	ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACCTGGCA	AATTAGGCTC	TGGAAGAGACG	3240
3241	CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
3301	CTTGATTTAA	GGCTTCAAAA	CCTCCGCAAA	GTCGGGAGGT	TCGCTAAAAC	GCTCGCGGTT	3360
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
3421	TCCTACGATG	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
3481	ACCCGTTCTT	GGAATGATAA	GGAAGACAG	CCGATTATFG	ATTGGTTTCT	ACATGCTCGT	3540
3541	AAATAGGAT	GGGATATTAT	TTTTCTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
3601	CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
3661	TTTGTCCGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
3721	GTTGGCGTTG	TAAATATG	CGATTCTCAA	TAAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780

FIG. 2-1

SUBSTITUTE SHEET

3 / 11

3781	ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
3841	TCCGGTGTIT	ATTCTTATTT	AACGCCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
3901	AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTT	ACGCGTTCTT	3960
3961	TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
4021	GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTIGATA	AATTCACAT	TGACTCTTCT	4080
4081	CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
4141	AGCGACGATT	TACAGAAGCA	AGGTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
4201	ATTAATAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
4261	TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
4321	TGTAACCTGG	TATTCAAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
4381	TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTT	4440
4441	TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
4501	TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
4561	TGATAATTCC	GCTCCTTCTG	GTGGTTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
4621	TTTTAAATTT	AATAACGTTT	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAG	4680
4681	GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
4741	TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
4801	AACTGACCAG	ATATTGATTG	AGGGTTTTGAT	TTTGTAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
4861	TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
4921	CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
4981	AGGGCTATCA	GTTCCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
5041	TATTTCTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAAAT	TCCCTTTTAT	5100
5101	TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAATAAAT	CCATTTTCAGA	CGATTGAGCG	5160
5161	TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
5221	TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
5281	TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
5341	CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
5401	AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
5461	ATACGTGCTC	GTCAAAGCAA	CCATAGTAGC	CGCCCTGTAG	CGGCGCATT	AGCGCGGCGG	5520
5521	GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTGACG	CCCGCTTCTT	5580
5581	TCGCTTCTTT	CCCTTCTTTT	CTCGCCACGT	TCCCGGCTT	TCCCGTCAA	GCTCTAAATC	5640
5641	GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
5701	ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
5761	CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	CTTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
5821	CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTTCGAA	CCACCATCAA	5880
5881	ACAGGATTTT	CGCCTGCTGG	GGCAAACCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
5941	CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCTT	6000
6001	GGCGCCCAAT	ACGCAAAACG	CCTCTCCCCG	CGCGTTGGCC	GATTCAATTA	TGCAGTGGC	6060
6061	ACGACAGGTT	TCCGACTGG	AAAGCGGCAA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
6121	TCACTCATTA	GGCACCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
6181	TTGTGAGCGG	ATAACAATTT	CACACGCGTC	ACTTGGGACT	GGCCGTCGTT	TTACAACGTC	6240
6241	GTGACTGGGA	AAACCCTGGC	GTTACCCAAG	CTTTGTACAT	GGAGAAAATA	AAGTGAAGAA	6300
6301	AAGCACTATT	GCACTGGCAC	TCTTACCGTT	ACCGTTACTG	TTTACCCCTG	TGACAAAAGC	6360
6361	CGCCCAGGTC	CAGCTGCTCG	AGTCAGGCCT	ATTGTGCCCA	GGGGATTGTA	CTAGTGGATC	6420
6421	CTAGGCTGAA	GGCGATGACC	CTGCTAAGGC	TGCATTCAAT	AGTTTACAGG	CAAGTGCTAC	6480
6481	TGAGTACATT	GGCTACGCTT	GGGCTATGGT	AGTAGTTATA	GTTGGTGCTA	CCATAGGGAT	6540
6541	TAAATTATTC	AAAAAGTTTA	CGAGCAAGGC	TTCTTAAGCA	ATAGCGAAGA	GGCCCGCACC	6600
6601	GATCGCCCTT	CCCAACAGTT	GCGCAGCCTG	AATGGCGAAT	GGCGCTTTGC	CTGGTTTCCG	6660
6661	GCACCAAGAG	CGGTGCCGGA	AAGCTGGCTG	GAGTGCGATC	TTCCTGAGGC	CGATACGGTC	6720
6721	GTCGTCCCCT	CAAACCTGGC	GATGCACGGT	TACGATGCGC	CCATCTACAC	CAACGTAACC	6780
6781	TATCCCATTA	CGGTCAATCC	GCCGTTTGTT	CCCACGGAGA	ATCCGACGGG	TTGTTACTCG	6840
6841	CTCACATTTA	ATGTTGATGA	AAGCTGGCTA	CAGGAAGGCC	AGACGCGAAT	TATTTTTGAT	6900
6901	GGCGTTCTTA	TTGGTTAAAA	AATGAGCTGA	TTTAACAAAA	ATTTAACGCG	AATTTTAAAC	6960
6961	AAATATTAAC	GTTTACAATT	TAAATATTTG	CTTATACAAT	CTTCCTGTTT	TTGGGGCTTT	7020
7021	TCTGATTATC	AACCGGGGTA	CATATGATTG	ACATGCTAGT	TTTACGATTA	CCGTTTCATC	7080
7081	ATTCTCTTGT	TTGCTCCAGA	CTCTCAGGCA	ATGACCTGAT	AGCCTTTGTA	GATCTCTCAA	7140
7141	AAATAGCTAC	CCTCTCCGGC	ATTAATTTAT	CAGCTAGAAC	GGTTGAATAT	CATATTGATG	7200
7201	GTGATTTGAC	TGTCTCCGGC	CTTTCTCACC	CTTTTGAATC	TTTACCTACA	CATTACTCAG	7260
7261	GCATTGCATT	TAAATATAT	GAGGGTTCTA	AAAAATTTTA	TCCTTGCGTT	GAAATAAAGG	7320
7321	CTTCTCCCGC	AAAAGTATTA	CAGGGTCATA	ATGTTTTTGG	TACAACCGAT	TTAGCTTTAT	7380
7381	GCTCTGAGGC	TTTATTGCTT	AATTTTGCTA	ATTCTTTGCC	TTCCTGTAT	GATTTATTGG	7440
7441	ACGTT						7445

FIG. 2-2

SUBSTITUTE SHEET



4 / 11

	10	20	30	40	50	60	
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
61	ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT	120
121	CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
181	JTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA	240
241	TCCGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAGG	TACTCTCTAA	TCCTGACCTG	300
301	TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAAACGCG	ATATTTGAAG	360
361	TCTTTCGGGC	TTCTCTTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAAGCCTC	TCGCTATTTT	600
601	GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
661	AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720
721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTJT	780
781	TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCCTA	AAATCGCATA	AGGTAATTCA	840
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTC	900
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG	960
961	AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
1021	TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
1081	GTCTGCGCCT	CGTTCGGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTTCGA	CACAATTTAT	1140
1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
1201	CAAAGATGAG	TGTTTTAGTG	TATTTCTTCG	CTCTTTTCGT	TTTAGGTTGG	TGCCCTCGTA	1260
1261	GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
1381	CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
1441	TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGT	TGTTTAAAGAA	1500
1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
1561	TTTTTGAGAG	TTTTCAACGT	GAAAAAATTA	TTATTTCGCA	TTCTTTTAGT	TGTTCTTTTC	1620
1621	TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAAATTA	1680
1681	TTTACTAACG	TCTGGAAGA	CGACAAAAT	TTAGATCGTT	ACGCTAATA	TGAGGGTTGT	1740
1741	CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
1801	TGGGTTCTTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
1861	TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
1921	ATTCGGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
1981	AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCTATTTT	2040
2041	CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAAGTG	TTTATACGGG	CACTGTTACT	2100
2101	CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
2161	TATGACGCTT	ACTGGAACGG	TAAATTTCAG	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
2221	GATGCAATCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCCTCAAC	TCCGTGCAAT	2280
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
2341	GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCGGGT	2400
2401	GATTTTGATT	ATGAAAAGAT	GGCAAAACGT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
2461	GAAAAACGCG	TACAGTCTGA	CGCTAAAGGC	AACTTGATT	CTGTGCTAC	TGATTACGGT	2520
2521	GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
2581	GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
2641	TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
2701	TTTGCTTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
2761	TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTCTACG	2820
2821	TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCGGT	2880
2881	TATTATTGCG	TTTCCTCGGT	TTCTTTCTGG	TAACCTTTGT	CGGCTATCTG	CTTACTTTTC	2940
2941	TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTTCA	GTTTCTTGCT	CTTATTATTG	3000
3001	GGCTTAACCT	AATTCTTGTT	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
3061	TTGTTTCAGGG	TGTTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC	3120
3121	TCCTGTGAAA	GGCTGCTATT	TTTATTTTGG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
3181	ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACGTGCA	AATTAGGCTC	TGGAAAGACG	3240
3241	CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
3301	CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAC	GCCTCGCGTT	3360
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
3421	TCCTACGATG	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAA	3480
3481	ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
3541	AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
3601	CGTTCGTCAT	TACGTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
3661	TTTGTCGGTA	CTTTATATTC	TCTTAATACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
3721	GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
3781	ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840

FIG. 3-1

SUBSTITUTE SHEET

5 / 11

3841	TCCGGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACAGG	GTCGGTATTT	CAAACCATTA	3900
3901	AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTT	ACGCGTTCTT	3960
3961	TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
4021	GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACAT	TGACTCTTCT	4080
4081	CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
4141	AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
4201	ATTAATAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
4261	TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
4321	TGTAACCTTG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAATAAG	4380
4381	TACTGTTACT	GTATAATCAT	CTGACGTTAA	ACCTGAAAT	CTACGCAATT	TCCTTATTTT	4440
4441	TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
4501	TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
4561	TGATAAATTC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
4621	TTTTAAATTT	AATAACGTTT	GGGCAAAAGG	TTTAATACGA	GTTGTGCAAT	TGTTTGTAAG	4680
4681	GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
4741	TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
4801	AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
4861	TTTTTCAATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
4921	CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTGTTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
4981	AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
5041	TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCTTTTAT	5100
5101	TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAATAAAT	CCATTTTCAG	CGATTGAGCG	5160
5161	TCAAATGTAT	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
5221	TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
5281	TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
5341	CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAGGATTCT	GGCGTACCGT	TCTGTCTTAA	5400
5401	AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
5461	ATACGTGCTC	GTCAAAGCAA	CCATAGTAGC	CGCCTGTAG	CGGCGCATT	AGCGCGGCGG	5520
5521	GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
5581	TGCTTTTCTT	CCCTTCTCTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	TCCCTAATTC	5640
5641	GCGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
5701	ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
5761	CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
5821	CTATCTCGGG	CTATTCTTTT	GATTTTATAA	GGATTTTGCC	GATTTGCGAA	CCACCATAAA	5880
5881	ACAGGATTTT	CGCTGCTGG	GGCAAACAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
5941	CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
6001	GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGGGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
6061	ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAA	GTGAGTTAGC	6120
6121	TCACCTATTA	GGCACCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
6181	TTGTGAGCGG	ATAACAATTT	CACACGCCAA	GGAGACAGTC	ATAATGAAAT	ACCTATTGCC	6240
6241	TACGGCAGCC	GCTGGATTGT	TATTACTCGC	TGCCCAACCA	GCCATGGCCG	AGCTCGTGAT	6300
6301	GACCCAGACT	CCAGATATCC	AACAGGAATG	AGTGTTAATT	CTAGAACCGG	TCACTTGCCA	6360
6361	CTGGCCGTCG	TTTTACAACG	TCGTGACTGG	GAAAACCCCT	GCGTTACCCA	AGCTTAATCG	6420
6421	CCTTGCAGAA	TTCCCTTTTG	CCAGCTGGCG	TAATAGCGAA	GAGGCCCGCA	CCGATCGCCC	6480
6481	TTCCCAACAG	TTGCGCAGCC	TGATTGGCGA	ATGGCCCTTT	GCCTGGTTTC	CGGCACCAGA	6540
6541	AGCGGTGCCG	GAAAGCTGGC	TGGAGTGCGA	TCTTCTTGAG	GCCGATACGG	TCGTCTGCCC	6600
6601	CTCAAACCTG	CAGATGCACG	GTTACGATGC	GCCCATCTAC	ACCAACGTAA	CCTATCCCAT	6660
6661	TACGGTCAAT	CCGCCGTTTG	TTCCCAACGA	GAATCCGACG	GGTTGTTACT	CGCTCACATT	6720
6721	TAATGTTGAT	GAAAGCTGGC	TACAGGAAGG	CCAGACGCGA	ATTATTTTTG	ATGGCGTTCC	6780
6781	TATTGGTTAA	AAAATGAGCT	GATTTAACAA	AAATTTAACG	CGAATTTTAA	CAAAATATTA	6840
6841	ACGTTTACAA	TTTAAATATT	TGCTTATACA	ATCTTCTGT	TTTTGGGGCT	TTTCTGATTA	6900
6901	TCAACCGGGG	TACATATGAT	TGACATGCTA	TTTATACGAT	TACCGTTTAT	CGATTCTCTT	6960
6961	GTTTGCTCCA	GACTCTCAGG	CAATGACCTG	ATAGCCTTTG	TAGATCTCTC	AAAAATAGCT	7020
7021	ACCCTCTCCG	GCATTAATTT	ATCAGCTAGA	ACGGTTGAAT	ATCATATTGA	TGGTGATTTC	7080
7081	ACTGTCTCCG	GCCTTTCTCA	CCCTTTTGAA	TCTTTACCTA	CACATTACTC	AGGCATTGCA	7140
7141	TTTAAATAT	ATGAGGGTTC	TAAAAATTTT	TATTTCTTGC	TTGAAATAAA	GGCTTCTCCC	7200
7201	GCAAAAGTAT	TACAGGGTCA	TAATGTTTTT	GGTACAACCG	ATTTAGCTTT	ATGCTCTGAG	7260
7261	GCTTTATTGC	TTAATTTTGC	TAATTTCTTG	CCTTGCCTGT	ATGATTTATT	GGATGTT	7317

FIG. 3-2

SUBSTITUTE SHEET

6 / 11

	10	20	30	40	50	60
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT
61	ATAGCTAAAC	AGGTTATTGA	CCATTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT
121	CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTAATTTA
181	GTTGCATATT	TAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA
241	TCTGCAAAAA	TGACCTCTTA	TCAAAAAGGAG	CAATTAAGG	TACTCTCTAA	TCCTGACCTG
301	TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG
361	TCTTTCGGGC	TTCTCTTTAA	TCTTTTGTAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT
421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAAC	GTTTAAAGCA
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT
541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAGCCTC	TCGCTATTTT
601	GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT
661	AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG
721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTJT
781	TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCCTA	AAATCGCATA	AGGTAATTCA
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTC
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATC	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG
961	AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC
1021	TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC
1081	GTCTGCGCCT	CGTTCGGGCT	AAGTAACATG	GAGCAGGTCTG	CGGATTTCGA	CACAATTTAT
1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTTCGCG	TTGGTATAAT	CGCTGGGGGT
1201	CAAGAGTAG	TGTTTTAGTG	TATTTCTTCG	CTCTTTTCGT	TTTAGGTTGG	TGCCCTCGTA
1261	GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT
1321	CAAAGCCTCT	GTAAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA
1381	CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA
1441	TGCGTGCGCG	ATGGTTGTGG	TCAATTGTCGG	CGCAACTATC	GGTATCAAGT	TGTTTAAGAA
1501	ATTACCTCTG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT
1561	TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCTTTTAGT	TGTTCTTTTC
1621	TTTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAAATTA
1681	TTTACTAACG	TCTGGAAAGA	CGACAAAAC	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT
1741	CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAAGT	TTACGGTACA
1801	TGGGTTTCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT
1861	TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT
1921	ATTCGGGGCT	ATACTTATAT	CAACCTCTCT	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA
1981	AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT
2041	CAGAATAATA	GGTTCGAAAC	TAGGCAGGGG	GCATTAAGTG	TTTATACGGG	CACTGTTACT
2101	CAAGGCACTG	ACCCCGTTAA	AACCTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG
2161	TATGACGCTT	ACTGGAACGG	TAAATTGAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA
2221	GATCCATTCT	TTTGTGAATA	TCAAGGCCAA	TGCTCTGACC	TGCCCTCAAC	TCTGTCAAT
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT
2341	GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGGTC	TGGTTCGGGT
2401	GATTTTGATT	ATGAAAAGAT	GGCAACCGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT
2461	GAAGAACGCG	TACAGTCTGA	CGCTAAAGGC	ACTGTTGATT	CTGTGCTAC	TGATTACGGT
2521	GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT
2581	GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCT	GTGACGGTGA	TAATTCACCT
2641	TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT
2701	TTTGCTTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA
2761	TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG
2821	TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCGGT
2881	TATTATTGCG	TTTCTCTGGT	TTCTTCTGG	TAACCTTTGT	GCCGTATCTG	CTTACTTTTC
2941	TTAAAAAGGG	CTTCGGTAAG	ATAGCTATCT	CTATTTCAAT	GTTTCTTGCT	CTTATTATTG
3001	GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTGTGACT
3061	TTGTTCAAGG	TGTTCAAGTT	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC
3121	TCTCTGTAAA	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG
3181	ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACGGCA	AATTAGGCTC	TGGAAAGACG
3241	CTCGTTAGCG	TTGGTAAGAT	TGAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT
3301	CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT
3421	TCCTACGATG	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAA
3481	ACCCGTTCTT	GGAAATGATA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT
3541	AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG
3601	CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT
3661	TTTGTGCGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT
3721	GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT
3781	ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT

FIG. 4-1

SUBSTITUTE SHEET

7 / 11

3841	TCCGGTGT	TTTCTATT	AACGCCTT	TTATCACACG	GTCGGTATT	CAAACCATTA	3900
3901	AATTTAGGT	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTT	ACGCGTTCTT	3960
3961	TGCTTTCGA	TTGGATTTCG	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
4021	GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCATAT	TGACTCTTCT	4080
4081	CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
4141	AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
4201	ATTAATAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
4261	TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
4321	TGTAACCTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAATAAG	4380
4381	TACTGTTACT	GTATATTCAI	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTT	4440
4441	TGTTTTACGT	GCTAATAATT	TTGATATGTT	TGTTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
4501	TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTTGCCATCA	TCTGATAATC	AGGAATTATGA	4560
4561	TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
4621	TTTTAAATTT	AATAACGTTT	GGGCAAAGGA	TTTAATACGA	GTTGTGCAAT	TGTTTGTAAG	4680
4681	GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
4741	TAGTGACCTT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
4801	AACTGACCAG	ATATTGATTG	AGGGTTTGGT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
4861	TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
4921	CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTGCTTGGGT	ATTTTAAATG	GCGATGTTTT	4980
4981	AGGGCTATCA	GTTCCGCGAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
5041	TATTTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
5101	TACTGTTGCT	GTGACTGGTG	AATCTGCCAA	TGTAATAAAT	CCATTTCAGA	CGATTGAGCG	5160
5161	TCAAATGTAT	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAAATATTGT	5220
5221	TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
5281	TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
5341	CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
5401	AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
5461	ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	5520
5521	GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
5581	TCGCTTTCTT	CCCTTCCTTT	CTCGCCACGT	TCGCGGCTTT	TCCCCGTCOA	GCTCTAAATC	5640
5641	GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
5701	ATTTGGGTGA	TGTTTACGTT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
5761	CGTTGGAGTG	CACGTTCTTT	AATAGTGGAC	CTTTGTTCCA	AAGTGGAAAC	AACTCAACCT	5820
5821	CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTTCGGAA	CCACCATCAA	5880
5881	ACAGGATTTT	CGCCTGCTGG	GGCAAACCCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
5941	CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
6001	GGCGCCCAAT	ACGCAAAACC	CCTCTCCCGG	CGCGTTGGCC	GATTCAATTA	TGCAGTTGGC	6060
6061	ACGACGAGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
6121	TCACTCATTA	GGCACCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
6181	TTGTGAGCGG	ATAACAATTT	CACACGCGTC	ACTTGGCACT	GGCCGTCGTT	TTACAACGTC	6240
6241	GTGACTGGGA	AAACCCTGGC	GTTACCCAAG	CTTTGTACAT	GGAGAAAATA	AAGTGAACAA	6300
6301	AAGCACTATT	GCACTGGCAC	TCTTACCGTT	ACTGTTTACC	CCTGTGGCAA	AAGCCCAAGT	6360
6361	CCAGCTGCTC	GAGTCGGTCT	TCCCCCTGGC	ACCCTCCTCC	AAGAGCACCT	CTGGGGGCAC	6420
6421	AGCGGCCCTG	GGCTGCCTGG	TCAAGACTAA	TTCCCGGAAC	CGGTGACGGT	GTCGTGGAAC	6480
6481	TCAGGCGCCC	TGACCAGCGG	CGTGCAACCC	TTCCCGGCTG	TCCTACAGTC	CTCAGGACTC	6540
6541	TACTCCCTCA	GCAGCGTGGT	GACCGTGCCC	TCCAGCAGCT	TGGGCACCCA	GACCTACATC	6600
6601	TGCAACGTGA	ATCACAAGCC	CAGCAACACC	AAGGTGGACA	AGAAAGCAGA	GCCCAATCTT	6660
6661	TGTACTAGTG	GATCCTACCC	GTACGACGTT	CCGGACTACG	CTTCTTAGGC	TGAAGGCGAT	6720
6721	GACCCTGCTA	AGGCTGCATT	CAATAGTTTA	CAGGCAAGTG	CTACTGAGTA	CATTGGCTAC	6780
6781	GCTTGGGCTA	TGGTAGTAGT	TATAGTTGGT	GCTACCATAG	GGATTAAATT	ATTCAAAAAG	6840
6841	TTTACGAGCA	AGGCTTCTTA	AGCAATAGCG	AAGAGGCCCC	CACCGATCGC	CCTTCCCAAC	6900
6901	AGTTGCGCAG	CCTGAATGGC	GAATGGCGCT	TTGCCTGGTT	TCCGGCACCA	GAAGCGGTGC	6960
6961	CGGAAAGCTG	GCTGGAGTGC	GATCTTCTCT	AGGCCGATAC	GGTCGTCGTC	CCCTCAAACCT	7020
7021	GGCAGATGCA	CGGTTACGAT	GCGCCCATCT	ACACCAACGT	AACCTATCCC	ATTACGGTCA	7080
7081	ATCCGCCGTT	TGTTCCACAG	GAGAATCCGA	CGGGTTGTTA	CTCGCTCACA	TTTAATGTTG	7140
7141	ATGAAAGCTG	GCTACAGGAA	GGCCAGACGC	GAATTATTTT	TGATGGCGTT	CCTATTGGTT	7200
7201	AAAAAATGAG	CTGATTTAAC	AAAAATTTAA	CGCGAATTTT	AACAAAATAT	TAACGTTTAC	7260
7261	AATTTAAATA	TTTGCTTATA	CAATCTTCTT	GTITTTGGGG	CTTTTCTGAT	TATCAACCGG	7320
7321	GGTACATATG	ATTGACATGC	TACTTTTACG	ATTACGGTTC	ATCGATTCTC	TTGTTTGCTC	7380
7381	CAGACTCTCA	GGCAATGACC	TGATAGCCTT	TGTAGATCTC	TCAAAAATAG	CTACCCTCTC	7440
7441	CGGCATTAAT	TTATCAGCTA	GAACGGTTGA	ATATCATATT	GATGGTGATT	TGACTGTCTC	7500
7501	CGGCCCTTCT	CACCCCTTTG	AATCTTTACC	TACACATTAC	TCAGGCATTG	CATTTAAAT	7560
7561	ATATGAGGGT	TCTAAAAATT	TTTATCTTTG	CGTTGAAATA	AAGGCTTCTC	CCGCAAAAGT	7620
7621	ATTACAGGGT	CATAATGTTT	TTGGTACAAC	CGATTTAGCT	TTATGCTCTG	AGGCTTTATT	7680
7681	GCTTAATTTT	GCTAATCTTT	TGCCTTGCCT	GTATGATTTA	TTGGACGTTT		7729
	10	20	30	40	50	60	

**FIG. 4-2**  
**SUBSTITUTE SHEET**

8 / 11

	10	20	30	40	50	60	
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
61	ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTAATCTA	ATGGTCAAAC	TAAATCTACT	120
121	CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
181	GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTG	AGCAATTAAG	CTCTAAGCCA	240
241	TCCGCAGAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAGGG	TACTCTCTAA	TCTGACCTG	300
301	TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAACGCG	ATATTTGAAG	360
361	TCITTGCGGC	TTCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAAATAGT	420
421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAAT	GTTTAAAGCA	480
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCGCGAG	TATTGGACGC	TATCCAGTCT	540
541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAGCCTC	TCGCTATTTT	600
601	GGTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
661	AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720
721	ATGAATCTTT	CTACCTGTAA	TAAATGTTGT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTAT	780
781	TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGT	900
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAAATG	960
961	AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCCGCTGGTC	1020
1021	TGTGACCCGT	TCATCTGTCC	TCTTTTAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
1081	GTCTGCGCCT	CGTTCGGGCT	AAGTAACATG	GAGCAGGTG	CGGATTTCTGA	CACAATTTAT	1140
1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
1201	CAAAGATGAG	TGTTTTAGTG	TATTCCTTTC	CCTCTTTCTG	TTTAGGTTGG	TGCCTTCGTA	1260
1261	GTGGCATTTAC	GTATTTTACC	CGTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCTT	1320
1321	CAAGCCCTCT	GTAGCCGTTG	CTACCCCTCG	TCCGATGCTG	TCCTTCGCTG	CTGAGGGTGA	1380
1381	CGATCCCAGCA	AAAGCGGCTT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
1441	TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAAGAA	1500
1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
1561	TTTTTGAGAG	TTTTCAACGT	GAAAAAATTA	TATTTCGCAA	TTCTTTTAGT	TGTTCTTTTC	1620
1621	TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAAATTCA	1680
1681	TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
1741	CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
1801	TGGGTTCTTA	TTGGGCTTGC	TATCCCTGAA	GTGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
1861	TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
1921	ATTCGGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
1981	AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
2041	CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACATG	TTTATACGGG	CAGTGTACTT	2100
2101	CAAGGCACCTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
2161	TATGACGCTT	ACTGGAACGG	TAAATTGAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
2221	GATCCATTCTG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGTT	GCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
2341	GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
2401	GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
2461	GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTGCTAC	TGATTACGGT	2520
2521	GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
2581	GGTGATTTTG	CTGGCTCTAA	TTCCCAAGTG	GCTCAAGTCG	GTGACGGTGA	TGAATCACCT	2640
2641	TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
2701	TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAECTTA	2760
2761	TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
2821	TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAACTATGCC	AGTTCTTTTG	GGTATTCGGT	2880
2881	TATTATTGCG	TTTCTCGGT	TTCTTCTG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
2941	TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CCTGTTTCTT	GCTCTTATTA	TTGGGCTTAA	3000
3001	CTCAATTCTT	GTGGGTTATC	TCTCTGATAT	TAGCGCTCAA	TTACCCTCTG	ACTTTGTTCA	3060
3061	GGGTGTTTCAG	TAAATTCTCC	CGTCTAATGC	GCTTCCCTGT	TTTTATGTTA	TTCTCTTGT	3120
3121	AAAGGCTGCT	ATTTTCATTT	TTGACGTTAA	ACAAAAAATC	GTTTCTTATT	TGGATTGGGA	3180
3181	TAAATAATAT	GGCTGTTTAT	TTTGTAACGT	GCAAAATAGG	CTCTGAAAG	ACGCTCGTTA	3240
3241	GCCTTGGTAA	GATTACAGGAT	AAAATTGTAG	CTGGGTGCAA	AATAGCAACT	AATCTTGATT	3300
3301	TAAGGCTTCA	AAACCTCCCG	CAAGTCGGGA	GGTTCGCTAA	AACGCCTCGC	GTTCTTAGAA	3360
3361	TACCGGATAA	GCCTTCTATA	TCTGATTTGC	TTGCTATTGG	GCGCGGTAAT	GATTCCTACG	3420
3421	ATGAAAATAA	AAACGGCTTG	CTTGTTCTCG	ATGAGTGC	TACTTGGTTT	AATACCCGTT	3480
3481	CTTGAATGA	TAAGGAAAGA	CAGCCGATTG	TTGATTGGTT	TCTACATGCT	CGTAAATTAG	3540
3541	GATGGGATAT	TATTTTCTT	GTTCCAGGACT	TATCTATTGT	TGATAAACAG	GCGCGTTCTG	3600
3601	CATTAGCTGA	ACATGTTGTT	TATTTCTGCT	GCTGGACAG	AATTACTTTA	CCCTTTGTCG	3660
3661	GTACTTTATA	TTCTCTTATT	ACTGCTCGA	AAATGCCTCT	GCCTAAATTA	CATGTTGGCG	3720
3721	TTGTTAAATA	TGGCGATTCT	CAATTAAGCC	CTACTGTTGA	GCGTTGGCTT	TATACTGGTA	3780
3781	AGAATTTGTA	TAACGCATAT	GATACTAAAC	AGGCTTTTTC	TAGTAATTAT	GATTCCGGTG	3840

FIG. 5-1  
SUBSTITUTE SHEET



9 / 11

3841	TTTATTCTTA	TTTAACGCCT	TATTTATCAC	ACGGTCGGTA	TTTCAAACCA	TTAAATTTAG	3900
3901	GTCAGAAGAT	GAAGCTTACT	AAAATATATT	TGAAAAAGTT	TTCACGCGTT	CTTTSTCTTG	3960
3961	CGATTGGATT	TGCATCAGCA	TTTACATATA	GTTATATAAC	CCAACCTAAG	CCGGAGGTTA	4020
4021	AAAAGGTAGT	CTCTCAGACC	TATGATTTTG	ATAAATTCAC	TATTGACTCT	TCTCAGCGTC	4080
4081	TTAATCTAAG	CTATCGCTAT	GTTTTCAAGG	ATTCTAAGGG	AAAATTAATT	AATAGCGACG	4140
4141	ATTTACAGAA	GCAAGGTTAT	TCACTCACAT	ATATTGATT	ATGTAAGTT	TCCATTAATA	4200
4201	AAGGTAATTC	AAATGAAATT	GTTAAATGTA	ATTAATTTTG	TTTTCTTGAT	GTTTGTTTCA	4260
4261	TCATCTTCTT	TTGCTCAGGT	AATTGAAATG	AATAATTCGC	CTCTGCGCGA	TTTTGATACT	4320
4321	TGGTATTTAA	AGCAATCAGG	CGAATCCGTT	ATTGTTTCTC	CCGATGTAAA	AGGTAAGTT	4380
4381	ACTGTATATT	CATCTGACGT	TAAACCTGAA	AATCTACGCA	ATTTCTTTAT	TTCTGTTTTA	4440
4441	CGTGCTAATA	ATTTTGATAT	GGTTGGTTCA	ATTCCTTCCA	TAATTCAGAA	GTATAATCZ	4500
4501	AACAATCAGG	ATTATATTGA	TGAATTGCCA	TCATCTGATA	ATCAGGAATA	TGATGATAAT	4560
4561	TCCGCTCTTT	CTGGTGTTTT	CTTTGTTCCG	CAAAATGATA	ATGTTACTCA	AACTTTTAAA	4620
4621	ATTAATAACG	TTCGGGCAAA	GGATTTAATA	CGAGTTGTCG	AATTGTTTGT	AAAGTCTAAT	4680
4681	ACTTCTAAAT	CCTCAAATGT	ATTATCTATT	GACGGCTCTA	ATCTATTAGT	TGTTAGTGCA	4740
4741	CCTAAAGATA	TTTTAGATAA	CCTTCCTCAA	TTCTTTTCTA	CTGTTGATTT	GCCAAGTGAC	4800
4801	CAGATATTGA	TTGAGGGTTT	GATATTGAG	GTTTCAGCAAG	GTGATGCTTT	AGATTTTTCA	4860
4861	TTTGCTGCTG	GCTCTCAGCG	TGGCACTGTT	GCAGGCGGTG	TTAATACTGA	CCGCCTCACC	4920
4921	TCTGTTTTAT	CTTCTGCTGG	TGGTTCGTTT	GGTATTTTTA	ATGGCGATGT	TTTAGGGCTA	4980
4981	TCAGTTTCGG	CATTAAGAC	TAATAGCCAT	TCAAAAATAT	TGTCTGTGCC	ACGTATTTCT	5040
5041	ACGCTTTTCAG	GTCAGAAGGG	TTCTATCTCT	GTTGGCCAGA	ATGTCCCTTT	TATTACTGGT	5100
5101	CGTATCTGAT	GTGAATCTGC	CAATGTAAAT	AATCCATTTT	AGACGATTGA	CGCTCAAAAT	5160
5161	GTAGGTATTT	CCATGAGCGT	TTTTCTGTT	GCAATGGCTG	GCGGTAATAT	TGTTCTGGAT	5220
5221	ATTACCAGCA	AGGCCGATAG	TTTGAGTTCT	TCTACTCAGG	CAAGTGATGT	TATTACTAAT	5280
5281	CAAGAAGTA	TTGCTACAAC	GGTTAATTTG	CGTGATGGAC	AGACTCTTTT	ACTCGGTGGC	5340
5341	CTCAGTGATT	ATAAAAACAC	TTCTCAAGAT	TCTGGCGTAC	CGTTCTGTCT	TAAAATCCCT	5400
5401	TTAATCGGCC	TCCTGTTTAT	CTCCGCTCT	GATTCCAACG	AGGAAAGCAC	GTTATACGTG	5460
5461	CTCGTCAAAG	CAACCATAGT	ACGCGCCCTG	TAGCGGCGCA	TTAAGCGCGG	CGGGTGTGGT	5520
5521	GGTTACGCGC	AGCGTGACCG	CTACACTTGC	CAGCGCCCTA	GCGCCCGCTC	CTTTCGTTTT	5580
5581	TTTTGCGCTG	TGGGGCAAA	CAGCGTGGAC	CGCTTGCTGC	AACTCTCTCA	GGGCCAGGCG	5640
5641	GTGAAGGGCA	ATCAGCTGTT	GCCCGTCTCG	CTGGTGAAAA	GAAAAACCAC	CCTGGCGCCC	5700
5701	AATACGCAAA	CCGCTCTCC	CCGCGCGTTG	GCCGATTCAT	TAATGCAGCT	GGCAGGACAG	5760
5761	GTTTCCCGAC	TGGAAGCGGG	GCAGTGAGCG	CAACGCAATT	AATGTGAGTT	AGCTCACTCA	5820
5821	TTAGGCACCC	CAGGCTTTAC	ACTTTATGCT	TCTGGGCTCG	ATGTTGTGTG	GCCTACGGCA	5880
5881	CGGATAACAA	TTTCACACGC	CAAGGAGACA	GTCATAATGA	AATACCTATT	CCCTACGGCA	5940
5941	GCCGCTGGAT	TGTTATTACT	CGCTGCCCAA	CCAGGCATGG	CCGAGCTCTT	CCCGCCATCT	6000
6001	GATGAGCAGT	TGAAATCTGG	AACTGCCTCT	GTTGTGTGCC	TGCTGAATAA	CTTCTATCCC	6060
6061	AGAGAGGCCA	AAGTACAGTG	GAAGGTGGAT	AACGCCCTCC	AATCGGGTAA	CTCCAGGAG	6120
6121	AGTGTACAG	AGCAGGACAG	CAAGGACAGC	ACCTACAGCC	TCAGCAGCAC	CCTGACGCTG	6180
6181	AGCAAAGCAG	ACTACGAGAA	ACACAAAGTC	TACGCTGCG	AAGTCACCCA	TCAGGGCCCTG	6240
6241	AGCTCGCCCG	TCACAAAGAG	CTTCAACAGG	GGAGAGTGT	CTAGAACCGG	TCACTTGGCA	6300
6301	CTGGCCGTCG	TTTTACAACG	TCGTGACTGG	GAAAAACCCTG	GCGTTACCCA	AGCTTAATCG	6360
6361	CCTTGACAGAA	TTCCCTTTTCG	CCAGCTGGCG	TAATAGCGAA	GAGGCCCGCA	CCGATCGCCC	6420
6421	TTCCCAACAG	TTGCGCAGCC	TGAATGGCGA	ATGGCGCTTT	GCCTGGTTTC	CGGCACCAGA	6480
6481	AGCGGTGCCG	CAAAGCTGGC	TGGAGTGCGA	TCTTCCTGAG	GCCGATACGG	TCGTCTGCCC	6540
6541	CTCAAACCTGG	CAGATGCACG	GTTACGATGC	GCCCATCTAC	ACCAACGTAA	CCTATCCCCT	6600
6601	TACGGTCAAT	CCGCCGTTTG	TTCCCAAGCA	GAATCCGACG	G6TTGTTACT	CGCTCACATT	6660
6661	TAATGTTGAT	GAAAGCTGGC	TACAGGAAGG	CCAGACGCGA	ATTATTTTTG	ATGGCGTTCC	6720
6721	TATTGGTTAA	AAAATGAGCT	GATTTAACAA	AAATTTAACG	CGAATTTTTA	CAAAATATTA	6780
6781	ACGTTTACAA	TTTAAATATT	TGCTTATACA	ATCTTCTCTG	TTTTGGGGCT	TTTCTGATTA	6840
6841	TCAACCGGGG	TACATATGAT	TGACATGCTA	GTTTACGAT	TACCGTTTCT	GGCTTCTCTT	6900
6901	GTTTGCTCCA	GACTCTCAGG	CAGTACCTG	ATAGCCTTTG	TAGATCTCTC	AAAAATAGCT	6960
6961	ACCCTCTCCG	GCATTAATTT	ATCAGCTAGA	ACGTTTGAAT	ATCATATTGA	TGGTGATTTG	7020
7021	ACTGTCTCCG	GCCTTTCTCA	CCCTTTTGAA	TCTTTACCTA	CACATTACTC	AGGCATTGCA	7080
7081	TTTAAATAT	ATGAGGGTTC	TAAAAATTTT	TATCCTTGCG	TTGAAAAAAA	GGCTTCTCCC	7140
7141	GCAAAAGTAT	TACAGGGTCA	TAATGTTTTT	GGTACAAACG	ATTTAGCTTT	ATGCTCTGAG	7200
7201	GCTTTATTGC	TTAATTTTGC	TAATTTCTTG	CCTTGCTGT	ATGATTTATT	GGATGTT	7260
7261							7320
7321							7380
7381							7440
7441							7500
7501							7557

FIG. 5-2

SUBSTITUTE SHEET

10/ 11

	10	20	30	40	50	60
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT 60
61	ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT 120
121	CGTTGCGAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA 180
181	GTTGCAATTT	TAAAAACATG	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA 240
241	TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAGG	TACTCTCTAA	TCCTGACCTG 300
301	TTGGAGTTTG	CTTCCGGTCT	GGTTTCGCTT	GAAGCTCGAA	TTAAAAACGC	ATATTTGAAG 360
361	TCITTCGGGC	TTCTCTTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT 420
421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAACGA 480
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT 540
541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAAGCCTC	TCGCTATTTT 600
601	GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT 660
661	AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG 720
721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT 780
781	TCITCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTCTCTA	AAATCGCATA	AGGTAATTCA 840
841	CAATTGATTAA	AGTTGAAATT	AAACCATCTC	AGACCCCAATT	TACTACTCGT	TCTGGTGTAT 900
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG 960
961	AATATCCGGT	TCTTGTCAGG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC 1020
1021	TGTACACCGT	TCATCTGTCC	TCTTCAAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC 1080
1081	GTCTGCGCCT	CGTTCGGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTTCGA	CACAACTTTAT 1140
1141	CAGGCGATGA	TACAAATCTC	CGTTGTAAGT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT 1200
1201	CAAAGATGAG	TGTTTTAGTG	TATTCCTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCTTCGTA 1260
1261	GTTGGCATTAC	GTATTTTACC	CGTTTAAATG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT 1320
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA 1380
1381	CGATCCCGCA	AAAGCGGCCT	TAACTCCCTC	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA 1440
1441	TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA 1500
1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCITTT	GGAGCCTTTT 1560
1561	TTTTTGAGAG	TTTTCAACGT	GAATAAAATTA	TTATTCGCAA	TTCTTTTAGT	TGTTCTTTTC 1620
1621	TATTTCTACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTTA 1680
1681	TTTACTAACG	TCTGGAAAGA	CGACAAAAC	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT 1740
1741	CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA 1800
1801	TGGGTTCTTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT 1860
1861	TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT 1920
1921	ATTCGGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA 1980
1981	AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT 2040
2041	CAGAATAATA	GGTTCGAAAA	TAGGCAGGGG	GCATTAAGTG	TTTATACGGG	CACTGTTACT 2100
2101	CAAGGCACTG	ACCCGTTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG 2160
2161	TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA 2220
2221	GATCCATTCT	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT 2280
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGTT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT 2340
2341	GCGGTTCTTG	AGGGTGGCGG	CTCTGAGGGA	GCGGTTCCG	GTGGTGGCTC	TGTTTCCGGT 2400
2401	GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT 2460
2461	GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT 2520
2521	GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT 2580
2581	GGTGATTTTG	CTGGCTCTAA	TTCCCAATAT	GCTCAAGTCG	GTGACGGTGA	TAATTACCTT 2640
2641	TAAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT 2700
2701	TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA 2760
2761	TTCCGTGGTG	TCTTTCGCTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG 2820
2821	TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT 2880
2881	TATTATTGCG	TTTCTCGGTT	TTCTTCTGTT	TAACTTTGTG	CGGCTATCTG	CTTACTTTTC 2940
2941	TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCAAT	GTTTCTTGCT	CTTATTATTG 3000
3001	GGCTTAACCT	AATTCTTGTT	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT 3060
3061	TTGTTTCAGG	TGTTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC 3120
3121	TCTCTGTAAA	GGCTGCTATT	TTCATTTTGT	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG 3180
3181	ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACCTGGCA	AATTAGGCTC	TGGAAAGACG 3240
3241	CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT 3300
3301	CTTGATTATA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT 3360
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT 3420
3421	TCTTACGATG	AAAAATAAAA	CGGCTTGCTT	GTTCCTGATG	AGTGCGGTAC	TTGGTTTAAT 3480
3481	ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT 3540
3541	AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG 3600
3601	CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAAT	TACTTTACCT 3660
3661	TTTGTCCGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCCTGCC	TAAATTACAT 3720
3721	GTTGGCGTTG	TAAATATGTT	CGATTCTCAA	TAAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT 3780
3781	ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT 3840
3841	TCCGGTGTTT	ATTCTTATTT	AACGCTTAT	TTATCACACG	GTCGGTATTT	CAAAACCTTA 3900
3901	AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTT	ACGCGTTCTT 3960
3961	TGTCTTGCGA	TTGGATTGTC	ATCAGCATTT	ATAGATAGTT	ATATAACCCA	AGCTTAAGCG 4020
4021	GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATCACTAT	TGACTCTTCT 4080

FIG. 6-1  
SUBSTITUTE SHEET

11/11

4081	CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
4141	AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
4201	ATTAATAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AAATTTTGTT	TCTTGATGTT	4260
4261	TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
4321	TGTAACCTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAATAAG	4380
4381	TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
4441	TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTTCAAGAGTA	4500
4501	TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
4561	TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
4621	TTTTAAATTT	AATAACGTTT	GGGCAAAAGGA	TTTAAATACGA	GTTGTCGAAT	TGTTTGATAA	4680
4681	GTCTAATACT	TCTAAATCCT	CAAAATGATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
4741	TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
4801	AACTGACCAG	ATATTGATTG	AGGGTTTGT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
4861	TTTTCTATT	GCTGCTGGCT	CTCAGCGTGG	CACCTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
4921	CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTGTTTGGT	ATTTTTAATG	GCGATGTTTT	4980
4981	AGGGCTATCA	GTTGCGCGAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
5041	TATTTCTTACG	CTTTGAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAAATG	TCCCTTTTAT	5100
5101	TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAATAAT	CCATTTTCTG	CGATTGAGCG	5160
5161	TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
5221	TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
5281	TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
5341	CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
5401	AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCAGCTT	5460
5461	ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATT	AGCGCGGCGG	5520
5521	GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACCTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
5581	TCGCTTTCTT	CCCTTCTTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
5641	GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCG	AAAAAACCCTG	5700
5701	ATTTGGGTGA	TGGTTACGTT	AGTGGGCGAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
5761	CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCT	AACTGGAACA	ACACTCAACC	5820
5821	CTATCTCGGG	CTATTTCTTT	GATTTATAAG	GGATTTTGCC	GATTTGCGAA	CCACCATCAA	5880
5881	ACAGGATTTT	CGCCTGCTGG	GGCAAAACCG	CGTGGACCGC	TTGCTGCAAC	TCTCTGAGGG	5940
5941	CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGCTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
6001	GGCGCCCAAT	ACGCAAAACG	CCTCTCCCCG	CGCGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
6061	ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
6121	TCACTCATTA	GGCACCCACG	GCTTTACACT	TTATGCTTCC	GGTCTGTAAT	TTGTGTGGAA	6180
6181	TTGTGAGCGG	ATAACAATTT	CACACGCCAA	GGAGACAGTC	ATAATGAAAT	ACCTATTGCC	6240
6241	TACGGCAGCC	GCTGGATTGT	TATTACTCGC	TGCCCAACCA	GCCATGGCCG	AGCTCTTCCC	6300
6301	GCCATCTGAT	GAGCAGTTGA	AATCTGGAAC	TGCCTCTGTT	GTGTGCCTGC	TGAATAACTT	6360
6361	CTATCCCAGA	GAGGCCAAAG	TACAGTGGAA	GGTGGATAAC	GCCCTCCAAT	CGGGTAACTT	6420
6421	CCAGGAGAGT	GTCACAGAGC	AGGACAGCAA	GAGACAGACC	TACAGCCTCA	CGAGCACCTT	6480
6481	GACGCTGAGC	AAAGCAGACT	ACGAGAAACA	CAAAGTCTAC	GCCTGCGAAG	TCACCCATCA	6540
6541	GGGCTGAGC	TCGCCCGTCA	CAAAGAGCTT	CAACAGGGGA	GAGTGTCTTA	GAACGCGTCA	6600
6601	CTTGGCACTG	GCCGTCGTTT	TACAACGTCG	TGACTGGGAA	AACCCTGGCG	TTACCCAAGC	6660
6661	TTTGATACATG	GAGAAAAATA	AGTGAACAAA	AGCACTATTG	CACCTGGCACT	CTTACCGTTA	6720
6721	CTGTTTACCC	CTGTGGCAAA	AGCCGCTTCC	ACCAAGGGCC	CATCGGTCTT	CCCCCTGGCA	6780
6781	CCCTCCTCCA	AGAGCACCTC	TGGGGGCACA	GCGGCCCTGG	GCTGCCTGGT	CAAGACTAAT	6840
6841	TCCCGGAACC	GGTGACGGTG	TCGTGGAATC	CAGGCGCCCT	GACCAAGCGG	GTGCACACCT	6900
6901	TCCCGGCTGT	CCTACAGTCC	TCAGGACTCT	ACTCCCTCAG	CAGCGTGGTG	ACCGTCCCTT	6960
6961	CCAGCAGCTT	GGGCACCCAG	ACCTACATCT	GCAACGTGAA	TCACAAGCCC	AGCAACACCA	7020
7021	AGGTGGACAA	GAAAGCAGAG	CCCAAATCTT	GTACTAGTGG	ATCCTACCCG	TACGACGTTT	7080
7081	CGGACTACGC	TTCTTAGGCT	GAAGGCGATG	ACCCTGCTAA	GGCTGCATTC	AATAGTTTAC	7140
7141	AGGCAAGTGC	TACTGAGTAC	ATTGGCTACG	CTTGGGCTAT	GGTAGTAGTG	ATAGTTGGTG	7200
7201	CTACCATAGG	GATTAATTA	TTCAAAAAGT	TTACGAGCAA	GGCTTCTTAA	GCAATAGCGA	7260
7261	AGAGGCCCGC	ACCGATCGCC	CTTCCCAACA	GTTGCGCAGC	CTGAATGGCG	AATGGCGCTT	7320
7321	TGCCTGGTTT	CCGGCACACG	AAGCGGTGCC	GGAAAGCTGG	CTGGAGTGCG	ATCTTCTCTA	7380
7381	GGCCGATACG	GTCTGCTGCC	CCTCAAACCTG	GCAGATGCAC	GGTTACGATG	CGCCCATCTA	7440
7441	CACCAACGTA	ACCTATCCCA	TTACGGTCAA	TCGCGCTTTT	GTTCCACCGG	AGAATCCGAC	7500
7501	GGGTTGTTAC	TCGCTCACAT	TTAATGTTGA	TGAAAGCTGG	CTACAGGAAG	GCCAGACGCG	7560
7561	AATTATTTTT	GATGGCGTTC	CTATTGGTTA	AAAAATGAGC	TGATTTAACA	AAAATTTAAC	7620
7621	GCGAATTTTA	ACAAAATATT	AACGTTTACA	ATTTAAATAT	TTGCTTATAC	AATCTTCTCTG	7680
7681	TTTTTGGGGG	TTTTCTGATT	ATCAACCGGG	GTACATATGA	TTGACATGCT	AGTTTTACGA	7740
7741	TTACCGTTCA	TCGATTCTCT	TGTTTGCTCC	AGACTCTCAG	GCAATGACCT	GATAGCCTTT	7800
7801	TTAGATCTCT	CAAAAATAGC	TACCCTCTCC	GGCATTAAAT	TATCAGCTAG	AACGGTTGAA	7860
7861	TATCATATTG	ATGGTGATTT	GACTGTCTCC	GGCCTTTCTC	ACCCTTTTGA	ATCTTTACCT	7920
7921	ACACAT ACT	CAGGCATTGC	TTTTAAATA	TATGAGGGTT	CTAAAAATTT	TTATCTTTGC	7980
7981	GTTGAAATAA	AGGCTTCTCC	CGCAAAAGTA	TTACAGGGTC	ATAATGTTTT	TGGTACAACC	8040
8041	GATTTAGCTT	TATGCTCTGA	GGCTTTATTG	CTTAATTTTG	CTAATTCCTT	GCCTTGCCTG	8100
8101	TATGATTTAT	TGGACGTT					8118

**FIG. 6-2**  
**SUBSTITUTE SHEET**



# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US91/07149

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12N 15/64, 15/70 U.S.C1.: 435/252.3, 320.1		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
U.S.C1.	435/69.7, 172.3, 252.3, 320.1	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched <sup>8</sup>		
APS, STN/MEDLINE, TERMS USED: SURFACE EXPRESSION VECTOR#, DIRECTED, EVOLUTION, SINGLE CHAIN ANTIBOD?.		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>9</sup>		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	WO, A, 89/06630 (FOX ET AL) 07 September 1989 see entire document.	1-75
Y	Nucleic Acids Research, Vol. 12, No. 9, issued SEPTEMBER 1984, BOSS ET AL, "Assembly of functional antibodies from immunoglobulin heavy and light chains synthesized in <u>E. coli</u> ", pages 3791-3806, see the abstract.	5-75
Y	Proceedings of the National Academy of Sciences, Vol. 86, issued AUGUST 1989, SASTRY ET AL, "Cloning of the immunological repertoire in <u>Escherichia coli</u> for generation of monoclonal catalytic antibodies: Construction of a heavy chain variable-region specific cDNA library", pages 5728-5732, see the abstract.	1-75
Y	Science, Vol 246, issued 08 December 1989, Huse et al, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", pages 1275- 1281, see entire document.	1-75
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
06 January 1992		21 JAN 1992
International Searching Authority		Signature of Authorized Officer
ISA/US		John D. Ulm

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y

Gene. Vol. 72, issued 1988, PARMLEY ET AL.  
 "Antibody-selectable filamentous fd phage  
 vectors: affinity purification of target  
 genes", pages 305-318, see entire document.

6-75

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers \_\_\_\_\_, because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:
  
2. ☐ Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:
  
3. ☐ Claim numbers \_\_\_\_\_, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
  
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
  
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.  
☐ No protest accompanied the payment of additional search fees.